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1. INTRODUCTION 
Siddha system of medicine is the most primitive medical system in India. It is 
mainly practiced in the southern part of India. 
The word siddha denotes achievements. This achievement was related to the 
discipline of mind and its superiority over body, and was accomplished through both 
Yoga and medicines. 
Eighteen Siddhars were said to have contributed towards the development of 
the siddha system of medicine. 
1.1 Fundamental principles 
The fundamental principles of siddha include theories of five elements and 
three humoral concepts. 
According to siddha medical science, the universe was originally consisted of 
atoms which contributed to the five basic elements like earth, water, fire, air and 
space. These five elements correspond to the five senses of the human body. 
The earth is the element which gives fine shape to the body including bones, 
tissues, muscles, skin, hair, etc., 
Water represents blood, secretions of the glands, vital fluid etc., 
Fire gives motion, vigor and vitality to the body. It helps in digestion, 
circulation and simulation. 
Space is the characteristic of man‟s mental and spiritual faculties. 
The physiological function of the body is mediated by three humours namely 
vatham, pitham & kabam. 
Vatham is formed by the basic elements space and air. It is connected with the 
functions of nervous system. 
Pitham is formed by fire. It plays a major role in digestion, metabolism, heat 
production & coloration of blood. 
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Kabam is by earth and water. It is connected with the reduction of heat and 
functions of various glands.  
1.2 Diagnostic aspects in siddha system 
The diagnosis of disease involves the identification of cause. Identification of 
causative factors is through the examination of pulse, urine, eyes, tongue, etc. 
Eight methods of examination – envakai thervukal is used to determine 
diagnosis, etiology, treatment and prognosis 
Noi nadal denotes the diagnosis of the affected disease. 
Noi muthal naadal means to find out the root cause of the disease. 
“஠ா ஠ி஦ண் மணாழி விழி ண஧பெட்தி஥ண் 
஠ாடி ஢஥ிசு ப௃வப ணருட்துப஥ாப௉டண்” 
- ந஠ாத் ஠ா஝஧் ந஠ாத் ப௅ட஡ா஝஧் 
1.3 Treatment aspects 
Siddhars have classified diseases into 4448 types and various medicines are 
indicated for these diseases. 
The drugs used by the siddhars could be classified into three groups: 
Thavaram - herbal product 
Thatu - inorganic subatoms 
Sangamam - animal products 
The siddha system of medicine comprises of various types of internal and 
external medicines. Internal medicines are 32 in number and the external medicines 
are 32 categories. 
Certain special therapies like varmam, yogam, thokkanam, ottradam also 
practiced in siddha system. 
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Kayakarpam is one of the unique special therapeutic divisions, which is 
especially treated for rejuvenation and increasing the life span. 
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2. AIM AND OBJECTIVES 
2.1 Aim 
The aim of this dissertation work is to undergo phase II study on kalanjapadai 
chooranam as internal medicine and semparuthi poo ennai as external medicine and 
yoga therapy. 
Objectives 
2.2 Primary objectives 
To evaluate the therapeutic efficacy of siddha formulation kottai karanthai chooranam 
as internal medicine and semparuthu poo ennai as external medicine in treatment of 
kalanjapadai (psoriasis) 
2.3 Secondary objectives 
1. To study the effect of yoga in the management of kalanjapadai along with the 
internal and external medicines 
2. To correlate the etiology, clinical features of kalanjapadai in siddha system 
with psoriasis in modern science. 
3. To screen the constituents present in the trial drug. 
4. To access the siddha basic principles like envagai theru, neerkuri, neikuri 
5. To analysis the trial medicine on the basis of Biochemical analysis and 
Pharmacological studies for anti-histamine anti-inflammatory 
6. To find out whether there are any side effects produced by the trial drugs, 
kottai karanthai chooranam and semparuthi poo ennai during the course of 
treatment. 
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3. REVIEW OF LITERATURES 
3.1 SIDDHA ASPECTS 
3.1.1 Definition 
 Based on the siddha literature, Kalanjagapadai is non-infectious inflammatory 
disease of the skin characterized by well-defined slightly raised dry, erythematous 
plaques with large adherent scales. 
3.1.2 Kalanjagapadai 
I. It is one of the tedious diseases that affect most of the people. 
II. About 2 – 3% of the total population is predominantly affected by this disease. 
III. It may affect both sexes. But predominantly affecting the females. 
IV. It mostly affects the age group of 5-35 years. 
V. It mainly affects the skin and mucous membrane. 
3.1.3 Vernacular name’s (நபறும஢த஥க்ந்) 
மபஞ்஢ருச ்மசதி஧்ந஠ாத் மசதி஧் உதி஥ந்஠ாத்  
                      -   சிட்ட ணருட்துப சி஦஢்பு                                                
மசண்஢ா஝ட்ு நடா஧ன஦்சி மசதி஧் உதி஥வ்ு஢்஢வ஝ சாண்஢஧் 
஢வ஝ த௃ஞ்ஞித மடா஦்று மசதி஧்஢வ஝. 
- அருங்கவ஧ச ்மசா஧் அக஥ப௅டலி 
3.1.4 LITERATURE EVIDENCES 
Siddha based definition 
 In siddha medicine the pancha bootham are elaborately described. According 
to siddha principle, thole (skin) is a part of prithivi. Skin is the largest organ in the 
human body. 
 In siddha system, skin disorders are brought under the clinical entity 
“Kuttam”. Among the siddha literature “Yugi Muni vaithiya kaviyam, Thirumoolar 
vaithiyam, Thanvanthiri are some of the sources of information on causes and the 18 
types of kuttam. 
 In the text book “Aathma Ratchamirtham ennum vaithya sarasangiragam” and 
“Thanvanthiri vaithiyam” the characteristic of kuttam are described clearly. 
 T.V. Sambasivam pillai has mentioned that in Tamil medicine „Kuttam‟ means 
cutaneous affections and so it is a comprehensive term used various skin diseases. 
 In this book “Sorikuttam” has been compared to psoriasis. 
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(Sorikuttam – A kind of leprosy with diffuse papillary eruptions without 
ulceration on the entire surface of the body marked by intense itching and burning 
sensation followed by exfoliation of the epidermis or browny. 
 Scales – Eczematous psoriasis lepra Itchyosis 
Among the 18 types of kuttam, thethru kuttam kajasarma kuttam and 
virpodaga kuttam resemble to that of kalanjgapadai. 
 
3.1.5 Aetiology 
 According to siddha literature, aetiology has been described below. 
 In “Thirumoolar vaithiyam” the aetiology is given as follows 
 
1.  விதாதிப௉ந் பெபாறு விநங்கித கு஝்஝ங்நகந் 
 சுதாதிக் கி஥஠்தி சுன஧் நணகட்டா ஧ாறுண் 
 ஢தாதி ணஞ்ணுந஢் ஢஧ பஞ்டி஡ா ம஧஝ட்ுண் 
 ஠ிதாதி புழு஠ா஧ாத் ஠ி஡்஦திக் கு஝்஝நண – திருபெ஧஥.் 
   
2.  “கு஝்஝ப௅஝஡் திந஥கமண஧்஧ாண் ஢஦க்குண்ந஢ாது 
 குழிகுழிதாத் கிருப௃பே஡ா஦் மகாந்ளுண் புந்நி – 96 குரு஠ாடி. 
 
3.  ஢பே஧் மணாழிபை஥ ்திந஥கட்தி஧்ää கிருப௃டாந஡ 
 ஢஥஠்துதி஥ி கு஝்஝ண் ந஢ா஧் புந்நி காணுண் 
 ணத஧துவுண் கிருப௃ப௉஠்டா ஠஝஠்து புக்கி஧் 
 நண஡ிதது ச஥சம஥஡ மபடிட்து புஞ்ஞாகுண் - 92 குரு஠ாடி. 
 
4.  “கி஥஠்தி சுன஡் நணகட்டா ஧ாறுண்” 
 Six types of skin diseases are caused by venereal disease. 
 “஢தாதி ணஞ்ணுந஢் ஢஧ பஞ்டி஡ா ம஧஝ட்ுண்” 
 Eight types of skin disease are caused by insect bites. 
 “஠ிதாதி புழு஠ா஧ாத் ஠ி஡்஦திக் கு஝்஝நண 
 Four types are caused by worm‟s infestations. 
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IN THANVANTHIRI VAITHIYAM 
 
“அறிவிண்றி வி஦஧஡ீஞ் சே஧ாகா஧஥் புசிக்கனாலு஥் 
துறநம௃ண்றி ச஡ாடா஡ த஡ாண்றந த஡ாட்டற஬த் - புசிக்கனாலு஥் 
குறந தகா஠்ட ஢ிசி஡்஡஥ாண குன஥ங்றக  ஦டுக்கனாலு஥் 
஢ிறநதகா஠்ட தத஧ிச஦ா஧் ஡஥்ற஥ ஢ி஡்தி஡்து சதேனாலு஥் 
஢ி஢்தி஡்துத் புந஡்தி஦ாந் சோ஥ ஢ிறனதகடத் பி஧ிக்கனாலு஥் 
஬஢்தி஡்துத் பூமே஬ா தோன்஥஢்தி஧ தா஬஡்஡ாலுஞ் 
ே஢்திக்கக் கந்஥ா஡஧் ஡ங்கறபக் கமே஡னாலு஥் 
த஡ா஢்தி஡்஡ குட்டச஧ாக஢் த஡ாடுக்கு த஥ண்றுற஧஡்஡ா஧் முண்சணா஧்” 
- ஡ண்஬஢்தி஧ி ற஬஡்தி஦ ச஧ாக஥் 
 
Guru Naadi Nool describes Aetiology as follows 
 
 “கிமேப௃ம௃ன் ஬஢்஡ ச஡ாட஥் ததமேகவு஠்டு 
 சகடக்ி ன஡ண் பி஧ிவு஡றண கி஧஥஥ாகத் 
 ததாமேப௃ ஬மே஥் ஬ாம௅த஬ன்னா஥் கிமேப௃஦ாசன 
 புழுக்கடி சதான் காணு஥து கிமேப௃஦ாசன 
 தேமேப௃ ஬மே஥் தவு஡்தி஧ங்கப் கிமேப௃஦ாசன 
 ச஡க஥தின் தோ஧ிக்குட்ட஥் கிமேப௃஦ாசன 
 துமேப௃஬மே஢் சுச஧ா஠ி஡ங் கிமேப௃஦ாசன 
 சூடே்முடண் கி஧ிறேத்தான் த஡ாழின் தே஦்வீச஧ 
- குமே஢ாடி 
 Intake of contaminated foods 
 Scolding the elders 
 Thinking of females 
 Destiny (Kanma vinai) 
 Intake of allergic foods 
 
The text book of “Sirappu Maruthuvam” describes the following etiological 
factors of kalanjaga padai. 
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஢஥ண்஢வ஥ ந஠ாதாக – of unknown aetiology and may be genetic  
பெப஥ி஧் ஑ருபருக்கு 
 
஧சு஡ டாபிடண் - Tonsillitis 
பு஢்புச பிஞிகந் - Respiratory diseases 
அதி஥ச்ச்ி - Depression, anxiety 
கா஧ ணாறு஢ாடுகந் - Due to changes in humidity 
஑ப்பாவண - Allergic disorder 
ண஡ உவநசச்஧் - Psychological disturbances 
 
Beta hemolytic streptococcal in guttate psoriasis. 
Anti-hypertensive drugs – Beta blockers 
They are 
1.   Propanolol 
2. Atenolol 
3. chloroquine 
4. Red oxide of copper  
5. Polio vaccine  
  ப௅டலித ணரு஠்துகந் குருக்கவநப௉ண் ஢வ஝வதப௉ண் உஞ்டு 
஢ஞ்ஞ஧ாண் எ஡்று கூ஦஢்஢஝ட்ுந்நது. 
  In Guru naadi nool says generally siddhars mentioned all the skin disease are 
caused by microorganism and macroorganism. 
“கிருப௃” – Microorganism and Macro organism 
“Thirumular has mentioned that the skin diseases are mentioned in three ways. 
1. Venereal origin and other mega diseases. 
2. Insect bites. 
3. Infection and infestations. 
“கு஝்஝ணது வி஝ க஥஢்஢ா஡் வி஝ ஠ீ஥ ்சூவ஧ 
  சுந஥ாஞிடட்டா஧் டாது மக஝ட்ுட் டடி஢்புஞ்஝ாகுண் 
ண஝்஝஦நப கிருப௃ மச஡்று ணருவுண் ந஢ாது 
  பவகதாத் கிருப௃ப௉஝ வி஝ரூ஥ ்மச஡்று  
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கு஝்஝ப௅஝஡் நடகமண஧்஧ாண் ஢஦க்குண் ந஢ாது 
  குழிகுழிதாத் கிருப௃பே஡ீ஥க்் மகாந்ளுண் புந்நி 
ட஝்஝஦நப கிருப௃ப௉஝ ரூ஥ா஧் ப஠்ட 
  சக஧ கு஝்஝ண் வி஝ க஥஢்஢ா஡் சா஦்஦஧ாநண 
- திருபெ஧஥ ்
Kuttam is named as a common word of chronic skin lesion as for the siddha text 
books. 
 Agasthiar had mentioned kanmam is the main cause for kutta noi. 
 Kanma varalaru (Psycho social cause) 
 “஢னவிவ஡தா஧் வி஝஢் பூசச்ி கடிட்டாலுண் 
  ஢ாடக஥க்்கு ஑ரு஠ாளுண் தீ஥ப்தி஧்வ஧ 
 உந விவ஡தாலூhபிக் மகாந்ந ப஠்ட 
  உஞ்வணத டபறிதாண஧் பெ஥க்்க஡் மசத்பா஥ ்
கநவிவ஡ப௉ந் தீ஥ப்தி஧்வ஧ கடி஡மணட்ட 
  கருவஞப௉ந்ந பூ஥ஞட்தி஧் கஞ்கா஝ச்ி 
அநவிவ஡ ஠ீ காணுப௅஡்ந஡ அக஧ச ்மசா஧்லு 
  அவ஝தாநண் வி஥஧் குறுகு பி஡்஡ா஧் நகநந 
வி஥஧் குறுகுண் காஅ஧் ஠ிப௃றுண் விண் ந஢ாந஧றுண் 
  ஢ா஥ா஡ நடகமண஧்஧ா஠் டடிட்து காணுண் 
஢ாடமண஧்஧ா஠் மபடிட்து ப௃க஢் புஞ்ஞாத் காணுண்  
ச஥சப௅஝஡் மசாறி க஥஢்஢ா஡் பிஞண் ந஢ா஧ 
நடாணுந் சா஠்வடதாநண வி஠்வட மகடுட்டடி வீங்குண் 
  ஠ா ஠஧்கிலி஠் ந஠ாத்க்கு ணரு஠்டத஥ாநட 
஠஧்ந஧ாவ஥ பீடிக்குங் கு஝ங் க஡்ணணாநண” 
- அகட்தித஥ ்஢஥ிபூ஥ஞண் 400.  
In yugimuni 800 he mentions 
 
“ஆேத்ேண்ந ததிதணடட்ு குட்ட஡்்஡ாலு஥் 
 அ஬஧஬஧க்ப் தே஦்கிண்ந அ஡஧்஥஡்஡ாலு஥் 
ச஡டிே ்தேண்ந சி஬ான஦஡்திலுே ்சிட்டங்கப் 
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 தே஦்஡஬஧க்ப் சி஬ ஢ிந஡்ற஡ த஠்஠ிணா஧க்ப் 
மூேத்ேண்ந தத஧ிச஦ாற஧ துடி஡்ச஡ா஧க்ப் 
 மூ஧க்்க஥ா஦் அறடக்கன஡்ற஡ ஋டுக்கிண்நா஧க்ப் 
ஆேத்ேண்ந திற஠஦பவின் குறந஢்஡ கூலி 
 தகாடுக்கண்தநா஧் குட்ட஡்்திந் கூடு஬ாசணா” 
- மெகிமுணி ததமேத௃ன் 800 
Yugimuni strongly described only psycho-social factors are the main causes. 
They are stress inducing factors. He has attributed the following causes. 
 Misbehavior in the temple 
 Sacrilege towards god 
 Humiliating the elders 
 Breach of trust 
 Praying low wages to workers 
The main factors behind the reasons are manifestations of stress which can be 
considered as precipitating factor. 
The psychic tranquility of the individual depends upon the harmony of social 
movements. 
 Hereditary also plays a important role in breeding Kalanjaga padai which 
appear in generations affecting several siblings and in such families the condition 
tends to be severe and persistant. 
  In yugi chinthamani, among the eighteen types of skin disease three types seen 
to be varients of kalanjaga padai. 
 But no description is available in agasthiar kanmakandam, he mentions. 
 “நச஥஠்்ட கு஝்஝மணாடு குவ஦ந஠ாத்கந் ப஠்ட 
 நசதிநகந் ண஧஥ாட அருண்பு மகாத்ட஧் 
 டா஥ிட்ட சீப மச஠்து பவடகந் மசத்ட஧் 
 டாத் ட஠்வட ண஡து ம஠ா஠்து ந஥ாக஠்டாந஡” 
- அகட்தித஥ ்க஡்ணகாஞ்஝ண் 
 Plucking buds 
 Domestic violence 
 Hurting the parents 
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In Manmurukiyam, he mentions 
 “இ஝ண் ம஢ாழு துஞவு மடாழிந஧ாடு ஢ருபண் 
 ஏ஡ப௃வப நபறு஢டுட ஧ாலுண் 
 ஠ஜ்சூ஦஧் ஠ஜ்சு கூடிதது ம஢ாறுண் 
 பிஞிப௉஦ ஧ாறுண் ஠ி஦ண் ம஢த஥ட்டுநண” 
 Change of place, food, work, climate and diurnal. 
 Toxins  by animal bites. 
In agasthiyar vaithyam he mentions 
 குத஧்பாத் குஷ்஝ண் சதங்குநண் ஠ீ஥ிழிவு சு஥க்கி஥ாஞி 
  ஠ீ஥வ஝஢்பு ஢ாஞ்டு பெ஧ பாத்வு 
 கத஧் பாப௉ பருங்கஞ்ஞி஧் குட்டாத் கடி஠் டசபாப௉ 
  கஞபாக ப௅஡் மசத்ட உபே஥ ்விவ஡டாந஡” 
- அகட்தித஥ ்வபட்திதண் 
 
 Skin disease 
 Tuberculosis 
 Diabetes 
 Fever 
 Diarrhoea 
These diseases occurs due to destiny 
Other cause 
 Excessive intake of allergic foods 
 Change of climate 
 Excessive intake of sweets, fried foods. 
 Chocolates and milk 
(B-lactone globulin – allergen in children) 
- Unavu maruthuvam 
In pararasa sekaram, He mentions As the causes 
 Kanmam 
 Stress 
 Excessive sleep 
Finally concludes,  
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 In our siddha system, siddhars not specified, the etiology for separate skin 
disease commonly they mentioned kanmam is one of the etiological factor.  Kanmam 
denoteds the genetic transmission. 
Even though genetic predisposed factor plays a key role among the etiological 
factors of psoriasis. 
It is well influenced by other factors like stress, climate changes etc. 
3.1.6 CLASSIFICATION 
ச஢ா஦் ஬றக 
மெகிமுணி-18 ஬றக 
புஞ்஝஥ீகண் சிகு஥ண் ணஞ்஝஧ண் கிடீ஢ண் 
வி஦்ந஢ா஝கண் க஥ஞண் அ஢஥ிசண் ச஥ண்ட஧ண் 
஢ாணண் கிரு஝்டிஞண் விச஥ச்ச்ிகண் டட்துரு 
க஛ச஥ண்ண் அவுதுண்஢஥ண் வி஢ாதிகண் சிட்துணா 
சடாரு சுநபடண்   
 
ட஡்ப஠்தி஥ி வபட்திதந஥ாகண் - 18 பவக 
க஢ா஧ண் சட஥ீக நடட்துரு ஢ாண 
சா஥ந்ணக விச஥ச்ச்ிக புஞ்஝஥ீக சுகா஠஠்தி 
உதுண்஢஥ ணஞ்஝஧ வி஦்ந஢ா஝க மபஞ் 
கிடீ஢ அருந஠ாத் ச஥ண்ட஧ சிட்துணா 
அ஧ச விபாதிக   
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வு.ஏ.சாண்஢சிபண் பிந்வந – 18 பவக 
஠ீ஥ ் மசங் வி஥஧்குவ஦ வி஥ஞ 
மபஞ்  ம஢ாறி சவ஝ கழி 
மசாறி ப஥ி தாவ஡ கிருப௃ 
கருங் எ஥ி திப௃஥ ் ஆகு 
஢஥஥ாச நசக஥ண் - 18 பவக 
மபஞ் புஞ்  ஢஝஥ ் ஆவஞ 
கருங் மசாறி ஢ஜ்சப஥ஞ் ப஦஝்சி 
மசங் புநி மபடி ச஦்஢ 
க஥஢்஢ா஡் நடண஧் பெ஧ சு஝வ஧ 
சிங்கப஡்஡ ப௅வந   
 
ஆ஡்஥஧டே்ாப௃஧஡்஥் ற஬஡்தி஦ ோ஧ேங்கா஧஥் - 4 ஬றக 
த஬஠்குட்ட஥்   கமேங்குட்ட஥் 
தேங்குட்ட஥்  ததமேவி஦ாதி 
Classification (ச஢ா஦் க஠ித்பு வி஬ா஡஥்) 
IN THANVANTHIRI VAITHIYAM 
 பாட பிட்ட ந஧஦்஢஡ட்தி஡் பா஥ந஥ாக஠் டா஡ம஡஡ினுண் 
 தீது கு஝்஝ மணழு஠்தீருங் கு஝்஝ண் ஢திம஡ா஡்று 
 நணாதுங் கு஝்஝ண் ஢திம஡஝ட்ு஝஡் ம஠ாத வபபேனு஦் ஢பப௅ண் 
 ந஢டக் குஞப௅ண் விதாதி஡் ப௅஡் பி஦க்குங் 
குஞப௅வ஝஢்ந஢ந஡. 
கு஝்஝ ந஠ாத் பாட பிட்ட சிந஧ட்ணட்தினுந் பாடண் பிட்டண் 
ஆகிதப஦்஦ா஧் உஞ்஝ா஡வப எ஡்றுண் 7 பவக கு஝்஝ங்கந் தீ஥ாது 
11 பவக கு஝்஝ங்கந் தீருண் எ஡்றுண் கூ஦஢்஢஝ட்ுந்நது. 
 
அசாட்தித கு஝்஝ண் - 7 ஡் ம஢த஥ ்
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 மசா஧்லுங் குஷ்஝ங் ஏழுபவகந஢஥ ் மசா஧்லி஦் 
கபா஧ஜ்ச஥ப்௄கண் 
 மப஧்லு ப௅துண்ந஢ா நணகிடி஢ண் விச஥ச்ச்ி ணஞ்஝஧ாக்கி஥ப௅ 
 ண஧்஧஧் டருப௄சி தகுவப தாகுண் ம஢தந஥ா டிதாகுண் 
 ப஧்஧விதாதிக் குஞணடவ஡ பகுடத்ு ஢ா஥ி லுவ஥஢்ந஢஡். 
சாட்திதண் ஢திம஡ா஡்றி஡் (11) ம஢த஥ ்
 பூஞ்஝டட் துருவிந஡ாடு சட஥ிசண் புஞ் ஝஥ீக஠் 
 டாஞ்டு வி஦்ந஢ாண் ஢ாணாவு஝ண் வணட஧ண் மபஞ் 
 கூஞ்஝டு காக ஠஠்தி சிட்துவண த஧ச ்குஷ்஝ண் கு஝்஝ண் 
 நபஞ்டித விபாதிநதாடுண் ஢திம஡ா஡்றுண் வி஥ிட்து காந஡ 
 
“In yugi muni vaidhya chinthamani” 
The kuttam has been classified into 18 types 
“மு஡்஡ாகு஥் குட்ட஢்஡ாசண ததிதணடட்ுக்கு஥் 
முணி஦ாண மெகி ஢ாண் தோன்னக் சகபா஦் 
த஡்஡ாகு஥் பு஠்ட஧கீ குட்ட஥ாகு஥் 
ததாமேகிண்ந விந்சதாடக குட்ட஥ாகு஥் 
த஡்஡ாகு஥் தா஥க்குட்ட஥், கேே்஧்஥குட்ட஥் 
பி஧ி஬ாண க஧஠்குட்ட஥், சிகு஧குட்ட஥் 
கி஡்஡ாகு஥் கிமேட்டி஠குட்டமு ஥ாத஥ண்சண 
குட்ட஥ா஥் ஸ்த஧ிசு குட்டத஥ாடு 
குடின஥ா஥் விே஧ே்ச்ிக்க் குட்ட஥ா஥் 
஬ட்ட்஥ா஥் விதாதி குட்டத஥ாடு 
஥மே஬னா கீடித குட்ட ே஧்஥஡ன 
திட்ட஥ாந் ச஡஡்திமே குட்டத஥ாடு 
சி஡்து஥ா குட்ட஥் ே஡ாமே குட்ட஥் 
துட்ட஥ாறு குட்ட஢் ஡ண்சணாதடக்க 
சு஦஥்தாண ததிதணடட்ு குட்ட஥ாேச்ே” 
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1. பு஠்ட஧கீ஥் - padar thamarai 
2. விந்சதாடக஥் – koppula perunoi 
3. தா஥஥் – sirangu perunoi 
4. கஜே஧்஥஥் – yaanai thol perunoi 
5. க஧஠஥் – kadhu perunoi 
6. சிகு஧஥் – tholperunoi 
7. கிமேட்டி஠஥் – karuperunoi 
8. அவுது஥்த஧஥் – athikkai perunoi 
9. ஥஠்டன஥் – valayu perunoi 
10. அத஧ிே஥் – vali perunoi 
11. விே஧்சிக஥் – sori perunoi 
12. விதாதிக஥் - senkuttam 
13. ே஧்஥஡ன஥் – tholvedippu perunoi 
14. கீடித஥் – pandri thol perunoi 
15. ச஡஡்மே – thadippu perunoi 
16. சி஡்து஥ா – naa perunoi 
17. ே஡ாமே – purai perunoi 
18. சுச஬஡஥் – venkuttam 
 
T. V. Sambasivam pillai has mentioned according to tamil medical science 
kuttam is of 18 types 
1. ஢ீ஧் – leprosy with exudation 
2. த஬஠் – white leprosy 
3. தோறி – psoriasis 
4. கமேங் – black leprosy 
5.ததமே஥் – true leprosy 
6. தேங் – macular leprosy 
7. ததாறி – leprosy with granules 
8. ஬஧ி – leprosy with fissures 
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9. ஋஧ி – leprosy with burning sensation 
10. வி஧ன்குறந – lepra mutilans 
11. ேறட – leprosy with confluent ulcers 
12. ஦ாறண – thick skinned leprosy 
13. திப௃஧் – anesthetic leprosy 
14. வி஧஠ –ulcerated leprosy 
15. கா஦் – nodular leprosy 
16. சூழி – a form with sloughing ulcers 
17. கிமேப௃ – leprosy with microbes 
18. சூநா – incurable leprosy 
Classification by Anubava vaithiya deva ragasiyam 
Based on three thodams, 18 types of kuttam has been classified as follows 
Vattam – kabala kuttam 
Pitham – avuthumbara kuttam 
Kabam – mandala kuttam, visharchiga kuttam 
Vadha pitham – rusiya jimmiga kuttam 
Pitha kabam – saruma kuttam, yoga kuttam, kidiba kuttam, siththuma kuttam, 
alasa kuttam 
Kaba vatham – vibathiga kuttam 
Thirithodam – thethuru kuttam, pundarega kuttam, satharu kuttam, virpodaga 
kuttam, bama kuttam, sarmathala kuttam. 
 
 “ஆட்ண஥஝ச்ாப௃஥ட்ண் வபட்தித சா஥சங்கி஥கண்” – 4 பவக 
1. மபஞ்கு஝்஝ண் 
2. மசங்கு஝்஝ண் 
3. கருங்கு஝்஝ண் 
4. ம஢ருவிதாதி 
 
திருபெ஧஥ ்- 18 பவக 
கி஥஠்தி நணகட்டா஧் பரு஢வப - 6 
பஞ்டி஡ா஧்   - 8 
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புழுபா஧்    - 4 
3.1.7 Comparative studies 
 Among the eighteen types of skin diseases (kuttam) described by yugi, clinical 
features of thethiru kuttam, virpodaga kuttam, sadharu kuttam resemble those of 
kalanjaga padai. 
ச஡஡்துமே குட்ட஥் 
 “ே஧்஥஢்஡ாண் சி஬த்தாக ஬ட்ட஠ி஡்துே ் 
 ேனற஬ சதான் த஬ளுக்குச஥ திணவு஠்டாகு஥். 
 ஬஧்஥஢்஡ாண் ச஧ாக஥து ப௃கவு஠்டாகு஥் 
 ஥ம௃த஧ன்னாஞ் சுமே஠்டுச஥ உ஠்றட஦ாகு஥் 
க஧்஥஢்஡ாண் பி஡்஡ சே஡்து஥ ப௃குக்கு஥் 
 கா஦஢்஡ாண் கதி஡்துச஥ திப௃மே஠்டாகு஥் 
 ஡஧்஥஢்஡ாண் ேடத஥ன்னா மூ஡னாகு஥் 
 ஡ாக்காண ச஡஡்திமேக் குஷ்ட஢்஡ாசண”. 
- மெகி முணி ற஬஡்தி஦ சி஢்஡ா஥஠ி 800. 
Annular erythematous lesions with whitish appearance, itching, oedema of the 
body and rolling of hairs like balls are the characteristic clinical features in the entity. 
விந்சதாடக குட்ட஥் 
 “புதுற஥஦ா஦்ே ்ே஧஧ீத஥ங்கு஡் திணவு஠்டாகு஥் 
 ததாமேத஬டி஦ா஦்஡் திக்தகண஡்தீக் தகாழு஢்து சதான 
 த஥துற஥஦ா஦் விடத்ட஧ிம௅஥் ஢ன்ன தா஥்பிண் 
 விஷத்தட஥் சதாசன ஡டி஡்து த஬மேத்பு ஥ாகு஥் 
 சுதுற஥஦ா஦் ப௃கே ்தோ஧ிம௅஢் சி஬த்பு஥ாகு஥் 
 தூக்கத஥ாடு ேஞ்ேனமு஥் ஡டித்பு஠்டாகு஥் 
 கண஡்஡விந் சதாடக஥ாண குட்ட஢்஡ாசண”. 
- மெகிமுணி ததமேத௄ன் 800. 
Characterized by elevated skin lesions with erythema and itching.  Burning 
sensation will be present on and off.  Usually these entities are associated with anxiety 
and despair. 
ே஡ாமே குட்ட஥் 
 “஋஡்஡ாண த஬஧ித்சதாடு திணவு஥ாகு஥் 
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 ஋பி஡ாண சேடட்ு஥஬ா஡஢் துந்த஡்தி 
 த஡்஡ாண கட்டித் பு஠்ணு஥ாகு஥் 
 தா஥்பு ச஡ான் சதாந்றிற஧஢்து தமே஡்துக் காணு஥் 
 வி஡்஡ாண மூக்சகாடு காது கண்ண஥்  
 ப௃க஡்துடித்தாஞ் ே஡ாமே குஷ்ட஢்஡ாசண”. 
     -மெகிமுணி ததமேத௄ன் 800. 
 
கதான ஬ா஡ க஧த்தாண் 
 “஋ண்ணவுற஧ ஬ா஡சி஧஡் ச஡ம௅ங்க ஧த்தணது 
 ப௃ண்னுமுக஡் ஡ாண்வீங்கு த஥஦்குபிமே஥் ச஬஡றண஦ா஥் 
 பிண்ணாண ே஢்து டசண பிட஧ிமு஡ னாப௃டங்கப் 
 ஡ண்ணாக த஢ா஢்துப௃க஡் ஡றனகணக்கு த஥ண்நறிச஦” 
- த஧஧ாே சேக஧஥் - சி஧ச஧ாக ஢ி஡ாண஥். 
ததாழித்புற஧ 
 ப௃ண்னு஥் முக஥் வீங்கு஥் த஥஦்குபிமே஥் ச஬஡றண 
உ஠்டாகு஥் ே஢்து பிட஧ி மு஡லி஦ இடங்கப் த஢ா஢்து ஡றன 
க஠க்கு஥்.   
 
“அறிச஦ ஢ீமே஥் ேனமு஥் தா஦்;஢் ஡ணன்சதா தனறி஢்து கு஡்து஠்டா஥். 
தோறிம௅஥் பிண்ண஧் ப௃கக்கா஦்஡்து துஞ்சு த஢஦்சதாந் கழி஢்ச஡ாடு஥் 
தறிம௅஥் ததாமேக்குே ்ோ஥்தத஧ணத் த஧ி஦ ஢ாறு஥் புனணாந்று஥் 
குறிம௅஥் ஬ா஡ சி஧க஧த்தாண் தகா஠்டா஧க் குந்ந கு஠ப௃ன்றனச஦” 
- த஧஧ாே சேக஧஥் - சி஧ச஧ாக ஢ி஡ாண஥் 
ததாழித்புற஧ 
 ஥ன஥் சிறு஢ீ஧் தேன்லு஥் சதாது அணன் சதான் ஋஧ிம௅஥்.  
அ஡்ச஡ாடு கு஡்஡ன் தோறிம௅஥் உ஠்டாகு஥்.  ச஡ா஦்஡்து ற஬஡்஡ 
த஢஦் சதான் சீ஫் கசி஢்ச஡ாடு஥்.  புனான் ஢ாந்ந஥் வீசு஥்.  இ஡ண் 
குறிகு஠ங்கப் காபாஞ்ேகதறட சதான் (P஦ப஬஧ட஦ே 
pப஫ேற஦பறப) கா஠த்தடுகிநது. 
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கதான த஬஠்குட்ட஥் 
 “ச஡ாந்றுத஬஠் குட்டஞ் தே஦்ம௅஥் கு஠஡்திறணே ்தோன்னக் சகபா஦் 
 ஢ீந்றிடுங் கன஥் சதானே ்தோறி஢்திடு ஢ீமே஥் தாம௅஥் 
 ஌ந்ந஥ா஦்ே ்ோ஥்தன் வீழு ப௃ழிபுனாண் ப௃ணச஬ ஢ாறு஥் 
 ஥ாந்ந஥ா஦்க் கதான ச஥ண்ச஥ன் ஬ந஠்டுகா திற஧ேே் னாச஥”. 
ததாழித்புற஧ 
 திமே஢ீறு ற஬க்கு஥் ஥஧க்கன஥் சதான் த஬ப்றப஦ாக 
இமேக்கு஥்.  தோறிச஦ாடு ஢ீமே஥் தாம௅஥் ோ஥்தன் சதான் விழு஥்.  
இ஡ண் குறிகு஠ங்கப் காபாஞ்ேக தறட சதான் 
கா஠த்தடுகிநது. 
கதான் த஬஠்க஧த்தாண் 
“வீறு஥் சி஧஡்தின் த஬஠்க஧த்தாண் கு஠஡்ற஡க் சகபா஦் த஥ன்லி஦சன 
 கூறு஥் புப்பி ஢ிந஥் த஬ளுத்தா஦்க் குறுத஢ந் தேதின்சதான் தகாதி஡்து விழு஥் 
 ஊறு மைமே஢் திணவு஠்டா ச஥ாசட த஦ாடுத்சதாந் க஧க஧க்கு஥் 
 ஥ாறு சதான வுடன்஬ந்று஥் ஬ாற஡ ம௃துவு ஥ோ஡்தி஦ச஥” 
- த஧஧ாே சேக஧஥் - சி஧ச஧ாக மே஡ாண஥். 
 
ததாழித்புற஧ 
 த஬஠்க஧த்தாணின் புப்பி சதாண்று.  த஬மேத்பு஠்டாகு஥்.  
குமேத஢ந் சதான் தேதின்கப் தகாதி஡்து விழு஥்.  உடன் ஊறி 
஢ீமேடண் திணவு஠்டாகு஥் ஥ாறு சதான் உடன் ஬ந்று஥்.  இ஡ண் 
குறிகு஠ங்கப் காபாஞ்ேகதறட சதான் (Exfoliative dermatitis). 
 According to thethuru kuttam, virpodaga kuttam, satharu kuttam, The clinical 
features are resemble to Kalanjagapadai. 
Clinical features 
 In the siddha text book sirappu maruthuvam, sirappu authored by Sri.Dr.R. 
Thiagaraja, Clinical features are described as, 
 The skin lesions are red in colour with raised margins and white ivory or 
silvery rough thick scales on removing the scales pin point blood-stained 
spots occurs. 
 The lesions vary in size either thin or thick layers. 
 In children these lesions may be like water drops. 
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 In severe cases lesions occur in the face, scalp and sometimes all over the 
body. 
 
3.1.8 IN A CHRONIC CASE 
 The skin lesion occurs in the extensor aspect of forearm. 
 In some cases these lesions appear over the palms and soles. 
 In some cases these lesions appear all over the body. 
 The lesions are coin shaped and there may be small pus formed lesions can 
be found. 
 In obese women, the lesions may occur over navel inguinal region and 
axilla with discharge.  Due to sweating, Itching may be associated. 
 The borders of the lesions are not be demarcated clearly. 
 On fourth of the patients have lesions over nails which are pink coloured 
and associated with ridges. 
 
3.1.9 PSORIATIC ARTHROPATHY (Kalanjaga Vatham): 
Kalanjaga padai is often associated with painful joints known as “Kalanjaga 
vatham”. It may affect any joint. The most often affected joints are inter-phalangeal 
joints. The terminal interphalangeal joints are usually involved as opposed to the 
proximal interphalangeal joints in “Uthira vatha suronitham” which is identical 
with rheumatoid arthritis.  
In these cases the affected fingers show nail changes. This condition is termed 
as “Psoriatic Arthropathica”.  The joints of fingers, ankles, knee and sacroiliac 
region are selectively affected. Those joints are swollen and painful with psoriatic 
lesions.  
Radiological changes are characteristic and consist of osteoporosis followed 
by increased density, diminished joint space, and erosion of joint surfaces followed by 
eventual destruction of the ends of bones. Ultimately, the joints become deformed.  
Yugi muni describes the clinical features of Kalanjaga vatham as follows; 
“பாடணாங் கா஧் வகபே஧் கு஥ங்கி஥ஞ்டுண் 
           பருட்து ச஠்து ப௅றுக்கிநத குவ஝஠்து ம஠ா஠்து 
஠ாடணா ஠வ஝ டானு஠்டா஡் மகா஝ாண஧் 
          ஠லி஠்துநண ப௅஝ணாகிக் க஥டு க஝்டிச ்
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நசடணா஠் ச஝஠்டானு ப௃க மபளுட்துட ்
  தி஡நபாடு சி஥ங்குணாத்ச ்நச஝்஢ணாகிக் 
காடணா தருசி மதாடு ணதக்கணாகுண் 
கருதிநத காநாஜ்சகணாண் பாடணாநண”  
- மசத்ப௉ந் 259 
“பாடணாங் கா஧் வகபே஧் கு஥ங்கி஥ஞ்டுண்” 
The joints of fingers, feet, ankles, knee and sacroiliac are selectively affected 
and these joints are painful. 
“஠ாடணா ஠வ஝ டானு஠்டா஡் மகா஝ாண஧் 
஠லி஠்துநண ப௅஝ணாகிக் க஥டு க஝்டிச” 
The deforming erosive arthritis targets finger and toe. Marked cartilage 
destruction and bony articulation results in loss of joint space and marked instability.  
 
“நசடணா஠் ச஝஠்டானு ப௃க மபளுட்துட ்
தி஡நபாடு சி஥ங்குணாத்ச ்நச஝்஢ணாகிக் 
காடணா தருசி மதாடு ணதக்கணாகுண் 
கருதிநத காநாஜ்சகணாண் பாடணாநண” 
The whole body becomes pale (anemic). Well-defined erythematous papules 
which are sharply demarcated appear on the skin. There is also loss of taste and 
giddiness. 
 
3.1.10 SIDDHA PATHOLOGY: 
Noi (Pini) 
 Definition : 
Whenever alterations occur in three vital humours, disease or noi occurs. 
“உ஝லு஝஡் பிவஞ஠்ட உபே஥ ்அனு஢விக்குண் 
இ஡்஢ உஞ஥ச்ச்ிக்கு ணா஦ா஡ உஞ஥ச்ச்ிநத பிஞி” 
An alteration in three vital humours may occur due to  
1. Dietary habits 
2. Seasonal variations 
3. Living place 
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4. Udal thathukkal 
5. Mukkutram 
6. Udal vanmai 
 
“ப௃கினுண் குவ஦பேனுண் ந஠ாத் மசத்ப௉ண் த௄ந஧ா஥ ்
பநி ப௅ட஧ா எஞ்ஞித பெ஡்று”. 
- கு஦ந் 
Therefore the deranged vatha, pitha kapha denotes disease. The diseases are 
reflected through the pulses in the three humours. 
Food variations: 
“புநி துப஥ ் விருஜ்சுங்கறி தா஥ ்
பூ஥ிக்குண் பாடண் 
஑நி ப௉ப஥ ்வக஢் ந஢றி஧் பிட்துச ்
சீறுண் - கிநி மணாழிநத 
கா஥஢்் பி஡ி஢்பு விஜ்சி஦் க஢ண் 
விஜ்சுஜ் ச஝்டி஥டச ்
நச஥ புஞ஥ ்ந஠ாதணுகாநட” 
 Sour and astringent increases vatham  
 Salt and bitter increases pitham  
 Pungent and sweet increases kabam 
 
Paruvakaalam (season): 
 The whole year is constituted by 6 seasons. They are 
 Karkalam  (August 16 to October 15)  
 Koothir kaalam (October 16 to December 15th)  
 Munpani kaalam (December 16 to February 15th)  
 Pinpani kaalam (February 16 to April 15th)  
 Elavenil kaalam (April 16 to June 15th)  
 Mudhuvenil kaalam  (June l6 to August 15th) 
  In each and every season routine changes will occur in the land, normal 
biological functions of individual, living things, plants, animals, human beings, which 
will modify normal physiology and make them susceptible to certain specific disease. 
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In my dissertation maximum cases occur in munpani kaalam.  
Nilam (land): 
It is divided into five types. They are 
1. Kurinchi 
2. Mullai 
3. Marutham 
4. Neithal 
5. Palai 
 
In kalanjaga padai, maximum cases commonly affected in marutham and some in 
neithal nilam. 
 
Based on dhanvandhari vaidhya rogam 
“முண்ணிறன ஬ா஡ பி஡்஡ சிசன஡்஥ண மூண்று ஥ங்கு஥் 
  பிண்ணி஦ ஡றுக்காம௅ப்ப ஢஧஥்பிணிந் பி஧ச஬சி஡்து 
 ஥ண்ணி஦ ஧஡்஡஥் ஡஠்஠ீ஧் ஥ாங்கிஷ஢் ச஡ான் தகாடு஡்ச஡ 
  ஦ண்ணி஦ ஬ண்ணங் காணு஥் ஥ாறகம௃ந் குட்ட஥ாச஥” 
- ஡ண்஬஢்தி஧ி ற஬஡்தி஦ ச஧ாக஥் 
 
஬ா஡஥் பி஡்஡஥் கத஥் மூண்று஥் சகடறட஢்து ஢஧஥்பின் சே஧்஢்து 
இ஧஡்஡஥் ஡஠்஠ீ஧் ஥ாப௃ே஥் ச஡ான் இ஬ந்றந தகடு஡்து 
஥ாறுதாடு உ஠்டாக்கு஥். 
 “குட்டச஧ாக஢்஡ாண் ஬஢்து குடிதகா஠்டாந் ே஧஧ீ஡்திலுப்ப 
  முடட்ுறு வி஦஧ற்஬ ம௄஧஥் ஬ந்றி஦ சூடே்ஞ்சூடே்ஞ் 
 திட்ட஥ா஦்க் கிமேப௃ம௅஠்டா஦் ச஡க஡்தின் ஥ம௃஧்ச஡ாதன஧ிவு 
  ேட்ட஥ா஥் ஢஧஥்பு திண்று ே஧஧ீ஡்திந் காணுத஥ண்சந” 
- ஡ண்஬஢்தி஧ி ற஬஡்தி஦ ச஧ாக஥் 
 வி஦஧ற்஬ம௃ண்ற஥ 
 கிமேப௃ம௅஠்டா஡ன் 
 ச஡ான் ஋஧ிவு 
 ஢஧஥்பு தாதித்பு  
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ஆகி஦ண குட்டச஧ாக஡்ற஡ த஡ாட஧்஢்து ஬மே஥். 
 
3.1.11 UYIR THATHUIYAL: 
Knowledge of three uyir thathus, seven udal thathus and six tastes will be 
helpful to do detailed study on the disease. 
For instance, the taste sweet is the combination of Mann and Neer. The kaba 
dosha also possess of same combination. So it is clear that excessive take of sweet 
will increase kaba kuttram. It can be balanced by the administration of "Thee" 
bootham containing taste. Similarly, administration of sour taste increases vatha 
kuttram that can be alleviated by opposite taste. The vatham further divided into ten. 
The classification and its functions are,  
A. VATHAM 
1. Pranan (Uyir Kaal) 
It is responsible for respiration and digestion. 
2. Abanan( Keezhnokku Kaal) 
It lies   below the umbilicus   responsible for the   downward expulsion of 
stools, urine and constriction of anal sphincter. 
3. Viyaanan (Paravu Kaal) 
It is responsible for the action of all organs, sensation and absorption of food. 
4. Uthaanan( Melonkku Kaal) 
It is responsible for the absorption and distribution of food. 
5. Samaanan (Nadu Kaal) 
It is responsible for the balancing of the other vayus; absorption of nutrition's 
and water balance of the body. 
6. Nagan 
It is responsible for the movements for eyelids. 
7. Koorman 
It is responsible for the sight, closing of eyelids, yawning and closure of 
mouth. 
8. Kirukaran 
It is responsible for the secretion of mouth and nose, appetite, sneezing, cough. 
9. Devathathan 
It is responsible for aggravating of the    emotional disturbances anger, lust 
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frustration, etc. 
10. Thananjayan 
It escapes from the head on the third day after death.  
Increased vaatham 
Emaciation, desire to hot food, shivering, abdominal bloating, 
constipation, sleeplessness, giddiness and laziness.  
Decreased vaatham 
Pain all over the body, low voice,  loss of attentiveness, unconsciousness and 
other diseases of increased kabam.  
In the cases of Kalanjaga padai 
Abanan -  Habitual Constipation. 
Viyaanan  -  Erythematous in the affected lesions of skin.  
Samaanan  - Due to other Vayu it is affected.  
Kirakaran  -  Polydipsia, polyphagia, loss of appetite.  
Devathathan  -  Insomia.  
The above Vayus are commonly affected.  
B. PITHAM 
The pitha dosha is further divided into five as follows, 
1. Anala Pitham (Aakku Anal) 
Its action is characteristic of thee. This is responsible for digestion of food. 
2. Ranjaga Pitham (Vanna Aeri) 
It is responsible for the colour and contents of the blood. 
3. Saathagam (Atralanki) 
It lies in the heart. It is responsible for the action after thinking. 
4. Prasagam ( Ollolithee) 
It is responsible for the complexion of 
skin.  
5. Aalosagam (Nokkazhal) 
It is responsible for the vision. 
Increased Pitham 
Yellowishness of eye, stools, urine and skin. Excessive thirst and appetite, 
burning sensation of body and sleeplessness. 
Decreased Pitham 
Hypothermia, loss of skin complexion and causes derangement of kabam.  
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In the cases of Kalanjaga padai 
Anala pitham  - Indigestion of food. 
Ranjagam -  Paleness of conjunctiva and tongue. 
Sathagam  - Difficulty to do the routine works properly and sluggishness. 
Pirasagam  - Dryness and roughness of skin.  
The above pithams are commonly affected. 
 C KABAM 
1. Avalambagam  
It causes diseases of the respiratory system when it is affected thereby 
indirectly affecting the other lyyams. 
2. Kilethagam  
Appetite and digestion may not be normal when it is affected.  
3.  Pothagam  
Derangement causes anorexia, 
distaste. 
4. Tharpakam 
Memory and perception of senses may be affected when this is deranged. 
5. Sandhigam 
Mobility of joints is affected due to drying up of the synovial fluid when 
sandhigam is abnormal. 
Increased kabam 
Increased salivation, inactiveness, heaviness of the body, impaired joint 
movement, dyspnoea, coughs and increased sleep. 
Decreased kabam 
Giddiness, flattening of chest increased sweating and palpitation. It is also 
important to know that the taste and activities which increase the Vaatham, pitham 
and kabam for the proper treatment of the diseases. 
In the cases of Kalanjaga padai 
   Kilethagam - loss of appitite was mainly affected. 
 Tharpagam - Burning sensation of eyes was affected in few cases. 
   Santhigam - Pain in joint affected in few cases 
  The above kabam are commonly affected. 
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3.1.12 SEVEN UDAL KATTUGAL 
There are seven primary body tissues which constitute the entire human body 
and all the organs of the various systems. 
1. Saaram 
It is the end product of digestive process. It gives strength to the body and 
mind. 
2. Senneer 
The saram after absorption is converted into senneer. It is responsible for 
knowledge, strength and health complexion.  
3. Oon 
It gives figure and shape to the body. It is responsible for the, movement of 
the body. 
4. Kozhuppu 
It lubricates the organs and thus facilitates their function. 
5. Enbu 
Gives shape to the body helps locomotion and protects vital organs. 
6. Moolai / machai 
Present in the core of the bone and it gives strength maintains the normal 
condition of the bone. 
7. Sukkilam /Suronitham 
Responsible for reproduction 
In the case of Kalanjaga padai out of seven udal attukkal  
Saaram : Dryness, roughness, tiredness.  
Senner  : Dryness, paleness of the skin.  
Oon   : Weakness of sense organ.  
Enbu  :Pain in the joints in chronic cases.  
3.1.13 UDAL VANMAI (Body Immunity) 
The Udal Vanmai is classified into 3 types. They are,  
 lyarkai Vanmai  
 Seyarkai Vanmai  
 Kaala Vanmai  
IYARKAI VAN MAI 
Natural immunity of the body itself by birth.  
 
31 
 
SEYARKAI VANMAI 
Improving the health by intake of nutritious  food materials,  activities  and 
Medicines.  
KAALA VANMAI 
Development of immunity according to age and the environment. 
When Udalvanmai is affected there may be a possibility of Kalanjaga 
Padai.  
3.1.14 PINIYARI MURAIMAI 
The method adopted to find out a disease in Siddha is known as P1N1YARI 
MURAIMAI. It is based on the following principles. 
 Poriyaal Arindhal  
 Pulanaal Therdhal  
 Vinavudhal. 
"Pori" is the five organs of perception namely Nose, Tongue, Eyes, Ears and 
Skin. "Pulan" is the five objects of senses Smell. Taste, vision auditory and sensation, 
respectively corresponding to "Pore". Poriyalarithai and Pulanal Therthal go hand in 
hand with the concept to examining the patients. "Pori" and "Pulan" with that of the 
"patient's .Pori" and" physicians Pulan". 
"Vinathal" is a method of inquiring the details of either the patient's problem 
that made him to approach the physician from his own or his /her attendants who 
accompany them. 
Along with, above mentioned principles is also carried out inspection in modern 
medicine. Besides, Thottuparthal (Palpation) and Thattiparthal (Percussion) are also 
used to diagnose a patient. 
The prime method adopted to diagnose the disease is by means of "Envagai 
Thervugal" (Eight types of investigations). Envagai Thervugal a physician' 
instruments and can be understood by the following verses. 
“஠ாடி஢் ஢஥ிசண் ஠ா ஠ி஦ண் மணாழி விழி 
ண஧ண் பெட்தி஥ண் ப௃வப ணரு஠்துப஥ாப௉டண்” 
- நடவ஥த஥ ்
 சிட்ட ணருட்துப ந஠ாத்஠ா஝஧் ந஠ாத் ப௅ட஧் ஠ா஝஧் தி஥஝ட்ு ஢ாகண் -1 
Envagai Thervugal constitue 
1. Naa 
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2. Niram  
3. Mozhi 
4. Vizhi  
5. Sparism  
6. Malam  
7. Moothiram  
8. Naadi 
1. Naa (Tongue) 
The colour, character and condition of the tongue change according to the 
changes of mukkutram. 
In Kalanjaga padai no abnormality is seen in Naa. 
2. Niram (Colour) 
Signs of Vatha, Pitha and Kaba colours, mixed colour cyanosis, pallor, flusing 
or Yellowish discoloration can be studies by means of Niram. 
In case of Kalanjaga padai white patches with silvery scales can be noticed at 
affected areas. 
3. Mozhi (Speech) 
  Constitutes high or low-pitched voice, slurring and incoherent Speech, nasal 
or crying, hoarseness of voice etc. 
In case of Kalanjaga padai, no abnormalities was ruled out in Mozhi. 
4. Vizhi (Eye) 
  Along with sight, anatomical lesions are noted, Burning of the eyes, 
lacarymation, mutation, colour change of the eyes also noted. In case of Kalanjaga 
padai, no abnormalities was ruled out in vizhi. 
5. Sparism (Palpation) 
  By palpation and inspection, the following information's were elicited. 
Temperature of the skin, whether uniformly hot or cold, thickness. Fissures soft/hard 
swelling, wrinkles, pigmentation of hairs etc. 
  In case of  Kalanjaga padai well defined macules, papules, thickening, 
roughness, pain and white silvery scaling of skin can be noticed at affected area. 
6. Malam (Stools) 
Vatha type      -  Hard, rough, dry, scanty and black. 
Pitha type       -  Loose stools, moderate in quantity. Yellowish red with  
     fermenting odour. 
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Kaba type       -  Clay or white coloured stools, huge in quantity with  
slimy, mucous and frothy bubbles. 
    Thontha type - Faecal matter possesses some of the features of two         
doshas. 
In case of Kalanjaga padai constipation was reported in some cases. 
 
7. Moothiram (Urine) 
The Examination of urine is classified under 2 headings. 
“அரு஠்து ணாறி஥டப௅ண் அவிந஥ாடணடாத் 
அஃக஧் அ஧஥ட்஧் அகா஧வூ஡் டவி஥஠்்டன஦்  
கு஦்஦ந பரு஠்தி உ஦ங்கி வபகவ஦ 
ஆடிக் க஧சட் டாவிநத காதும஢த் 
மடாரு ப௅கூ஥ட்்டக் கவ஧கு஝் ஢டு஠ீ஥ி஡் 
஠ி஦க்குறி ம஠த்க்குறி ஠ிருப௃ட்ட஧் க஝ந஡.” 
- சிட்ட ணருட்துபாங்க சுருக்கண் 
Neerkuri - Niram, Edai, Manam, Nurai, Enjal  Neikuri   
Neerkuri 
 “஬஢்஡ ஢ீ஧க்்க஧ி த஦றட ஥஠஥் த௃ற஧ ஋ஞ்ேதனண் 
 றந஢்தி஦ லுபற஬ ஦றநகுது முறநச஦”. 
- சி஡்஡ ஥மே஡்து஬ாங்க சுமேக்க஥் 
 Niram indicates the colour of the urine voided. 
  Edai indicates the specific gravities of urine. 
 Manam indicated the smell of the urine voided. 
 Nurai indicates the frothy nature of the urine voided. 
 Enjal indicates the quantity (increases or decreased) of urine voided. 
In addition, frequency of Micturation, abnormal constituents, such as sugar, 
protein, presence of blood, pus, renal crystals also to be noted. 
In Kalanjaga padai patient straw coloured urine is noted. Poly urea can be noted 
in some cases. 
(b) Neikuri: 
The specialty of neikuri is stated in the following verse: 
 “ஐக்குறி மகாடுப஝ பா஡ின ஧ண஥஠்்நடா஥ ்
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 வகக்குறி மட஥ி஠்ட ஠ங் க஝வுவநட் துதிட்நட 
 மணத்குறி ஠ி஦஠்மடா஡ி விழி ஠ாவிருண஧ண் 
 வகக்குறி ப௅னபதூ உங்க஦்஦ா஥ ்டண்ப௃னுண் 
 ம஢ாத்க்குறி மணத்குறி புகலுமண ப஥க்்குண்” 
- சிட்ட ணருட்துப ந஠ாத் ஠ா஝஧் ந஠ாத் ப௅ட஡ா஝஧் தி஥஝ட்ு 
The collected specimen as said above is to be analysed by following method. The 
specimen is kept open in a glass dish or china clay container. It is to be examined 
under direct sunlight, without shaking of the vessel. Then add one drop of gingelly oil 
at a distance of 1/2" or 3/4" height observe keenly the direction it spreads with in few 
minutes, and conclude the diagnosis.  
The character of Vatha Neer  
“அ஧த஬஠் ஢ீ஠்டி ணஃச஡ ஬ா஡஥்” 
When the drop of oil spreads like a snake, it indicates Vatha Neer. 
The Character of Pitha Neer  
“ஆழிந஢ா஦் ஢஥வி஡் அஃநட பிட்டண்” 
When the drop of oil spreads like a ring, it indicates Pitha Neer.  
The Character of Kaba Neer  
“ப௅டம்டாடத்ு ஠ி஦்கி஡் மணாழிப மட஡் க஢நண” 
When the drop of oil remains as that of a pearl, it indicates Kaba Neer. 
The Character of Thontha Neer  
“அ஧வின் ஆழிம௅஥் ஆழிம௃ன் அ஧வு஥் 
 அ஧வின் மு஡்து஥் ஆழிம௃ன் மு஡்து஥்” 
- சி஡்஡ ஥மே஡்து஬ ச஢ா஦் ஢ாடன் ச஢ா஦் மு஡ணாடன் தி஧டட்ு 
Thontha Neer 
Ring in the Snake Snake in the ring Pearl in the snake Pearl in the ring  
8. Naadi (pulse): 
Naadi is responsible for the existence of life and can be felt on inch below the 
wrist on the Radial side by means of palpation with the tips of index, middle and ring 
fingers corresponding to vatham, pitham and kabam. 
These humors vatham, pitham and kabam exist in the ratio 1: ½ : ¼ normally the 
arrangement in this ratio leads to various disease entities. 
In the Kalanjaga vatham he following types of naadi were observed. They are, 
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i. Vatha kabam 
ii. Vatha Pitham 
3.1.15 LINE OF TREATMENT (NOI NEEKAM) The aim of noi neekam is based 
on 
1. To bring the three doshas in equilibrium. 
2. Treatment of the disease accordingly the signs and symptoms. 
3. Pathiyam 
Siddha system of medicine is based on the mukkutra theory and hence the 
treatment is mainly aimed to bring down the three doshas to its equilibrium state and 
there by restoring the physiological consitions of several thathus. 
“விந஥சஞட்டா஧் பாடண் டாழுண் 
பண஡ட்டா஧் பிட்டண் டாழுண் 
஠சித அஜ்சஞட்டா஧் க஢ண் டாழுண்”. 
- சிட்ட ணருட்துபாங்கச ்சுருக்கண் ஢.எஞ்.662 
 Vatha disease can be brought down by Viresanam. 
 Pitha disease can be brought down by Vamanam.  
 Kaba disease can be brought down by Anjanam. 
“பாடண஧ாது நண஡ிமக஝ாது” 
- நட஥஡் நசக஥஢்஢ா 
சிட்ட ணருட்துப ந஠ாத்஠ா஝஧் ந஠ாத்ப௅ட஧் ஠ா஝஧் தி஥஝ட்ு 
஢ாகண் -1 ஢.எஞ்.363 
Hence, Kalanjaga padai occurs due to the vitiation of vatham it can be set right 
by giving viresanam.  
Treatment of disease: 
In addition to this following medications are practiced in the Siddha system .  
 Aha maruthugal (Internal medicines)  
 Pura maranthugal (external medicines) 
 Restriction regarding food habits and routine day to day life style.  
 Sirappu Maruthuvam - a special feature of Siddha medicine like 
Pranayamam, 
Yoga. 
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After the thiridoshas are brought down to its equilibrium state, the signs and 
symptoms of disease should be treated properly. For the study.  
AHA MARUTHUVAM 
 kottai karanthai chooranam 
PURA MARUTHUVAM  
 Semparuthi Poo Ennai   
Restriction Regarding food and Habits 
1. Avoid bitter guard, guava, egg, fish, chicken 
2. Avoid alcohol, smoking etc., 
3. Obese must be restricted. 
4. Since it is a chronic and not a life threatening disease, it should not be loaded 
with 
heavy drags. 
5. The meditations should calm the mind just free from stress and strain 
6. The patches should be washed with lukewarm water, to remove the scales 
everyday early morning. After the bath, external applications are to be applied 
thereafter. 
7. Avoid allergic food items. 
“ம஢ருஜ் நசாந ப௃றுங்குண் ம஢ருண் கண்பு 
ப஥கு காரு஝஡் பாவனபே஡் காமதாடு 
உவ஥ மகாந் ஢ாக஦் மகநி஦்று ப௄஡் உஞ்டிடி஧் 
வி஥ிபடாத் க஥஢்஢ானு ப௃கு஠்டடநட” 
- ஢டா஥ட்்ட குஞ சி஠்டாணஞி 
3.1.16 SPECIAL NON DRUG THERAPEUTICS 
Several special medicaments of non-drug therapeutic like Yoga, Pranayamam, 
Asanas, Kalpa medicines are employed in Siddha systems. 
These are employed during diseased state and for the prevention of diseases 
during healthy days. In Kalanjagapadai, patients are also advised to follow 
Pranayamam, Yoga and Asanas, in order to avoid the remissions and exacerbation of 
this disease.  
PRANAYAMAM 
It is a form of Kayakalpa method. By practicing this one can prevent any 
disease. This is explained in the following verse, 
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Figure 3.1.1 Pranayama 
3.1.17 YOGA 
Yoga is maintained by the body in a particular posture for a particular period of 
time. This is totally different from the ordinary exercise. Yoga vitalises, both physical 
body and the mental set-up unlike exercise which tones only the muscles. The 
common benefits are, 
 It tones the internal organs. 
 It prevents obesity and disease. 
 It maintains normal circulation to all the organs of the body. 
 It is very safeguard for all the vital organs. 
 It avoids laziness, enhances pure mind and cleverness and memory power. 
There will be no problems like psychosomotive disturbances if practised 
daily.  
3.1.18 ASANAS 
Retarding skin disease the following Asanas can be advised  
I. - PADMASANA (LOTUS POSE) 
TECHNIQUE: 
1. Keep the right foot on the left thigh 
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2. Start bouncing the right knee.  If the bouncing knee easily touches the floor, 
then bend the left knee, take hold of the left foot with both hands, gently glide 
it over the crossed right leg and place it on the right thigh. 
3.  This will give symmetrical placement of the Padmasana legs and you are 
in lotus position. 
4. The hands should be kept on the knees with palms open, and the thumb and 
second finger of each hand should touch forming a letter O.  
Benefits: 
1. This is an extremely good pose for meditation and concentration. 
2. It has a calming effect on the mind and the nerves. 
3. This pose keeps the spine erect. Helps to keep the joints in flexible condition. 
4. Helps to develop a good posture. 
5. It allows the body to be held completely steady for long periods of time. 
6. It holds the trunk and head like a pillar with the legs as the firm foundation. 
 
Figure 3.1.2 Padmasana 
2. ே஧஬்ாங்காேண஥் - SARVANGASANA (THE SHOULDER STAND) 
TECHNIQUE 
1. Lie flat on your back. Inhale deeply while raising your legs and spine until 
the toes point to the ceiling. 
2. The body rests on the shoulders and the back of the neck. The body is 
supported by the hands, which are placed on the center of the spine 
between the waist and the shoulder blades. Keep your spine and legs 
straight. 
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3. Breathe slowly and deeply with the abdomen and concentrate on the 
thyroid gland. On a male, the thyroid gland is located behind the Adams 
apple. For women, it is located in the same area which is a few inches 
above the sternal notch (hollow of the neck where the neck joins the rest 
of the body.) or approximately half way up the neck from the sternal 
notch. Stay in this position for about two minutes. 
4. To come out of this posture, just bend your knees, curve your back and 
slowly return to lying on the floor while exhaling. First bend your knees, 
put the palms on the floor, then curving the spine, gradually unfold it the 
way one unrolls a carpet. When your entire back touches the floor, 
straighten the knees, take a deep breath and slowly lower your legs to the 
ground while breathing out. 
5. If you wish, you may go straight into the next posture (the 'reverse 
posture') instead of lying down. 
 
Figure 3.1.3 Sarvangasana 
Benefits 
1. The main benefit of the shoulder stand is to get the thyroid gland working 
at peak efficiency. It's the thyroid gland which is mainly responsible for 
your correct weight and youthful appearance.  
2. The shoulder stand also regulates the sex glands.    
3. It vitalizes the nerves, purifies the blood and promotes good circulation, 
strengthens the lower organs and helps them to stay in place. 
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4. It gives a healthy stretch to the neck muscles. 
5. It is beneficial for people suffering from poor circulation, constipation, 
indigestion,  asthma and reduced virility. 
6. This pose is especially recommended for women after childbirth and for 
those, from painful menstruation, other female disorders, and seminal 
weakness. 
7. The sanskrit name for this posture sarvangasana means 'all the body' 
3. ே஬ாேண஥் - The Corpse Posture (Shava-asana) 
Instruction 
1. Lie flat on your back with your legs together but not touching, and your 
arms 
2. Close to the body with the palms facing up. 
3. Keep your eyes gently closed with the facial muscles relaxed and breathe 
deeply and slowly through the nostrils. 
4. Starling at the top of the head and working your way down to the feet, 
bring to each part of your body, consciously relaxing it before proceeding 
on to the next.  
5. Remain in the shava-asana for between 3 and 5 minutes or longer. If you 
become sleepy while in the shava-asana begin to breathe a bit faster and 
deeper. 
Comments 
1. The goal of the shava-asana is for the body and minds to be perfectly still and 
relaxed. Not only should the body be motionless and at ease, but the mind as 
well should be quiet, like the surface of a still lake. 
2. It goes without saying that the shava-asana will take some time to perfect. It 
will find the simple exercise of focusing your attention on each part of your 
body and consciously directing the breath there to be a great help with this 
posture. 
3. There are two common obstacles that can prevent you from fully benefiting 
from this posture: sleepiness and a restless mind. If our mind is restless or 
wondering focus your attention on all of the bodily sensations you're 
experiencing. Bring your mind to the sensation of the floor beneath you or on 
the rhythm of your breath. 
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4. While practicing your Yoga-asana routine you should always begin and end 
each session with the shava-asana. 
 Durations/Repetitions: 
1. We recommend that you begin your period of yoga-asana practice with at least 
3-5 minutes of shava-asana. 
2. Return to it periodically thought your posture session to relax and rejuvenate 
the body/mind and then conclude your session with at least 3-5 minutes more.  
Benefits 
1. This asana relaxes the whole psycho-physiological system. 
2. It should ideally be practiced before sleep; before, during and after asana 
practice,particularly after dynamic exercises such as surya namaskara. 
3. When the practitioner feels physically and mentally tired. It develops body 
awareness.  
4. When the body is completely relaxed, awareness of the mind increases, 
developing pratyahara.  
 
Figure 3.1.4 The Corpse Posture 
3.1.19 PATHIYAM 
Diseases mainly occur due to wrong diet habits. Siddhars stressed this in every 
aspect of treatment and prevention from further occurrences. This view is well 
understood in this verse. 
“ணரு஠்மட஡ நபஞ்஝ாபாண் தாக்வகக்கு 
அரு஠்திததுத஦்஦து ந஢ா஦்றி ப௉ஞி஡்” 
- கு஦ந் 
During diseased states, diet restrictions or pathiyam are strictly to be followed. 
These are to be administered to normalize the deranged doshas and for the good 
manifestation of given medicines to be more effective. I his is given in the verse, 
“஢ட்திததட்தி஡ாந஧ ஢஧஡் உஞ்஝ாகுண் ணரு஠்து 
42 
 
 ஢ட்திதங்கந் ந஢ா஡ா஧் ஢஧஡் ந஢ாகுண் - ஢ட்திதட்தி஧் 
஢ட்திதநணமப஦்றி டருண் ஢ஞ்டிட஥க்்கு – ஆடலி஡ா஧் 
஢ட்திதநண உட்திமத஡்று ஢ா஥”் 
- நடவ஥த஥ ்மபஞ்஢ா. 
So it is very essential to and here pathiyam strictly for the early cure of the 
Diet 
  Food habits that reduce the vatham, pitham, kabam to the normal level has to 
be taken. Patients are strictly convinced to avoid all the non-vegetarian items except 
goat's flesh. Avoidance of the following food items were also strictly advised. 
Agathi keerai - Leaves of sesbania grandiflora. 
Seeni avaraikai - Cynampsis psoratoides. 
Pagarkai - Bitter guard. 
Poosanikai - Great pumpkin. 
Perum payaru - Cow - gram. 
Solam - Maize. 
Kanam - Horsegram. 
Motchai - Flac bean. 
Elumicham pazham - Lemon (citrus medica) 
Rich protein foods - Consists of histidine. 
 
The rich protein consists of glucogenic amino acids. This amino acids on 
metabolism undergoes decarboxylation to yield histamine in the presence of an 
enzyme histidine decarboxylase. 
Histamines acts on skin and causes urticaria and anaphylactic reactions. So in 
order avoid skin complications, avoid dietary foods which are rich in highly 
biological value proteins.  
Habits: 
Patients avoid smoking, alcohol etc., advised to have timely diet.   
 
ANUPANAM IN SIDDHA SYSTEM: 
 “அனு஢ா஡ட்டாந஧ தவின்டண் ஢லிக்குண் 
 இ஡ிடா஡ சுக்கு க஡்஡஧் இஜ்சி – பினுப௅டகா஧் 
 நகாநணதண் ஢ா஧் ப௅வ஧஢்஢ா஧் நகாம஠த் நட஡் மப஦்றிவ஧ ஠ீ஥ ்
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 ஆப௃வடதா஥ாத்஠்து மசத்த஧ாண்”. 
- நடவ஥த஥ ்மபஞ்஢ா 
Siddha system considers anupanam as an important and sometimes more important 
than the medicine itself, without a knowledge of the importance of anupanam, 
success in the treatment is not possible. Kottai karanthai chooranam is given with hot 
water two times a day. 
 
காத க஦்஢ண் 
Advised to take (Rejuvenation) " காத க஦்஢ண்" to render the body invulnerable. 
All patients were also advised to follow siddhers preventive measures which would 
give immortality of body and soul, quoted in "Pathartha Guna Chinthamani" as 
follows. 
 
 “தி஡்஡ ப௃஥ஞ்டுந்ந சிக்க ப஝க்காண஦் 
 ந஢ஞ்ஞி஡்஢ா ம஧ா஡்வ஦஢் ம஢ருக்காண஧் - உஞ்ணுங்கா஧் 
 ஠ீ஥ச்ுருக்கி நணா஥ ்ம஢ருக்கி ம஠த்ப௉஥க்கி ப௉ஞ்஢ப஥ட்ண் 
 ந஢ருவ஥க்கி஦் ந஢ாநண பிஞி 
- ஢டா஥ட்்ட குஞ சி஠்டாணஞி 
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3. REVIEW OF LITERATURES 
3.2 MODERN ASPECTS 
 
3.2.1 Skin anatomy 
The skin is the largest organ of the body, with a total area of about 20 square feet. The 
important function of the skin is to protect us from microbes, ultraviolet radiation 
from the sun, helps to regulate body temperature and permits the sensation of touch, 
heat and cold. 
Skin has three layers: 
a) Epidermis 
b) Dermis 
c) Hypodermis 
d) Epidermis 
It is the outermost layer of the skin that is visible to the eye. It provides protection to 
the body. It does not contain any blood vessels. 
Epidermis 
Types of cells present in epidermis are keratinocytes, melanocytes, Langerhans cell 
and merkel cells. 
Keratinocytes: 
It is the most common type of cell in the epidermis and is responsible for the synthesis 
of the protein keratin. They originate from the basal layer which is the deepest layer 
of the epidermis and gradually move up to the outside layer of the epidermis. They are 
shed from the skin and replaced by new maturing cells. 
Melanocytes: 
It is present throughout the basal layer of the epidermis. These cells are responsible 
for the production of melanin, which contributes to the color of the skin of the 
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individual. It also helps to protect the body from ultraviolet radiation present in 
sunlight that can damage the DNA of the skin cells. 
 
Figure 3.2.1 Skin Structure 
Langerhans cells: 
It is produced in the bone marrow and also present in the epidermis. Langerhans cells 
detect foreign substances and infections as a part of the immune system of the skin. 
Merkel cells: 
It originates from neural crest cells and is responsible for the perception of gentle 
touch. They are present in the epidermis in specific areas of the skin, such as nail beds 
and genitalia. 
3.2.2 Structure: 
The epidermis consists of stratified, squamous epithelial cells. It has 5 layers from 
deep to superficial namely, 
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i. Stratum basale or basal layer 
ii. Stratum spinosum or spiny layer 
iii. Stratum granulosum or granular layer 
iv. Stratum lucidum 
v. Stratus corneum 
Stratum basale: 
It is otherwise known as stratum germinativum. It is the deepest epidermal layer and 
attaches the epidermis to the basal lamina. Dermal papilla increases the strength of the 
connection between the epidermis & dermis. Stratum basale is a single layer of cells 
primarily made of basal cells. Merkel cells and melanocytes are the cell types that are 
found dispersed among the basal cells in the stratum basale. 
Stratum spinosum: 
It is spiny in appearance due to the protruding cell process that joins the cells via a 
structure called a desmosome. The stratum spinosum is composed of 8 to 10 layers of 
keratinocytes, formed as a result of cell division in stratum basale. Interspersed among 
the keratinocytes of this layer is a type of dendritic cell called the Langerhans cell 
which functions as a macrophage by engulfing bacteria, foreign particles and 
damaged cell. The keratinocytes begin the synthesis of keratin and release a water-
repelling glycolipid that helps prevent water loss from the body. 
Stratum granulosum: 
It has a grainy appearance due to further changes to the keratinocytes as they are 
pushed from the stratum spinosum. The cells become flatter, their cell membranes 
thicken, and they generate large amounts of protein named keratin, which is fibrous, 
and keratohyalin that accumulates as lamellar granules within the cells. These two 
proteins make up the bulk of the keratinocyte mass in stratum granulosum. The nuclei 
and other cell organelles disintegrate as the cells die leaving behind the keratin, 
keratohyalin and the cell membranes will form the stratum lucidum and the stratum 
corneum. 
Stratum lucidum: 
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The Stratum lucidum is a smooth translucent layer of the epidermis located just above 
the stratum granulosum and below the stratum corneum. This thin layer of cells is 
found only in the thick skin of the palms, soles and digits. The keratinocytes that 
compose the stratum lucidum are dead and flattened. These cells are densely packed 
with eleiden, a clear protein rich in lipids which gives these cells their transparent 
appearance & provides a barrier to water. 
Stratum corneum: 
It is the most superficial layer of the epidermis & the layer exposed to the outside 
environment. There are 15 to 30 layers of cells in the stratum corneum. This dry, dead 
layer helps prevent the penetration of microbes and provides a mechanical protection 
against abrasion. The cells in this layer are shed periodically and are replaced by cells 
pushed up from stratum granulosum. The entire layer is replaced during a period of 
about 4 weeks. 
Dermis: 
The dermis is considered as the core of the integumentary system. It contains blood 
and lymph vessels, nerves and other structures such as hair follicles and sweat glands. 
The dermis is made up of two layers of connective tissue that comprise an 
interconnected mesh of elastin and collagenous fibers, produced by fibroblasts. The 
more superficial papillary layer serves as an anchor point for the epidermis above and 
is intimately connected to the deeper reticular layer. 
Papillary layer: 
It is made up of loose, areolar connective tissue. Within the papillary layer are 
fibroblasts, a small number of fat cells adipocytes, and an abundance of small blood 
vessels. The papillary layer also contains phagocytes, defensive cells that help fight 
bacteria and other infections, lymphatic capillaries, nerve fibers and touch receptors 
called the meissner corpuscles. 
Reticular layer: 
It is present under the papillary layer. It is much thicker composed of dense irregular 
connective tissue which resists forces, and flexibility of the skin. Elastin fibers 
provide some elasticity to the skin. 
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Hypodermis: 
The hypodermis is also called as subcutaneous layer. It is present directly below the 
dermis and serves to connect the skin to the underlying fascia surrounding the 
muscles. It consists of well vascularized, loose, areolar connective tissue and 
abundant adipose tissue, which functions as a mode of fat storage. 
Skin appendages: 
a. Nails 
b. Hair follicles 
c. Sweat gland  
a. Apocrine sweat gland 
b. Eccrine sweat gland 
d. Sebaceous gland 
Nails: 
Nail is a horny plate that grows on the back of each finger and toe at its outer end. 
Finger and toe nails are made of a tough protective protein called alpha-keratin. The 
nail consists of the nail plate, the nail matrix and the nail bed below it. The lunula is 
the visible part of the matrix, the whitish crescent shaped base of the visible nail. 
Hair follicle: 
A hair follicle anchors each hair into the skin. Hair is made of a tough protein called 
keratin. This hair follicle regulates hair growth. 
Hair growth occurs in cycles consisting of 3 phases: 
1. Anagen-growth phase 
2. Catagen-transitional phase 
3. Telogen-resting phase 
Sweat gland: 
Sweat glands are small tubular structures of the skin that produce sweat. It is a type of 
exocrine gland. There are two main types of sweat glands.  
a. Apocrine glands 
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b. Eccrine glands 
Apocrine glands are mostly limited to the axilla and perianal areas in humans. Eccrine 
glands are distributed almost all over the body. 
Sebaceous gland: 
A small gland in the skin which secretes a lubricating sebum into the hair follicles in 
order to lubricate the skin & hair. Sebaceous glands develop from the same tissue that 
gives rise to the epidermis of the skin. Sebum is made of triglycerides, wax esters, 
squalence and metabolites of fat producing cells. 
3.2.3 Physiology of skin: 
Protective function: 
Skin forms the covering of all the organs of the body and protects these organs from 
bacterial infection. The lysozyme secreted in skin destroys the bacteria. The 
keratinized stratum corneum of epidermis offers resistance against toxic chemicals 
like acids and alkalis. During injury or skin infection, the keratinocytes secrete 
cytokines like interleukins & tumor necrosis factor, & interferon which play important 
role in immunological reactions, tissue repair & wound healing. Skin protects the 
body from ultraviolet rays of sunlight.  
Sensory function: 
Skin is considered as the largest sense organ in the body. It has many nerve endings, 
which form the specialized cutaneous receptors. These receptors are stimulated by the 
sensations of touch, pain, pressure or temperature sensation and convey these 
sensations to the brain via afferent nerves. 
Storage function: 
Skin stores fat, water, chloride and sugar. It can also store blood by the dilation of the 
cutaneous blood vessels. The skin is also a good store house of ergosterol vitamin D. 
Synthetic function: 
Vitamin D3 is synthesized in skin by the action of ultraviolet rays from sunlight on 
cholesterol. 
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Regulation of body temperature: 
Excess heat is lost from the body through skin by radiation, conduction, convection 
and evaporation. Sweat glands of the skin play active part in heat loss by secreting 
sweat. The lipid content of sebum prevents loss of heat from the body in cold 
environment. The temperature of the skin depends upon the amount of blood flowing 
through the vessels.  
Regulation of water and electrolyte balance: 
Skin regulates water balance and electrolyte balance by excreting water and salts 
through sweat. The sebum also acts as a lubricant for the drying effects of the 
atmosphere in skin. This is important because it prevents our body from losing all the 
necessary nutrients and minerals that it stores up.  
Excretory function: 
Skin can excrete small quantities of waste materials like urea, salts and fatty 
substance. Sweat is one of the ways that skin removes waste from the body.  
Absorptive function: 
Skin can absorb the fat soluble substances and some ointments. Due to the absorptive 
capabilities of skin, the cells comprising the outermost 0.25 to 0.4 mm of skin can be 
supplied by external O2 rather than via the underlying capillary network. 
Iontophoresis, also called electromotive drug administration, is a technique that uses a 
small electric charge to deliver a medicine or other chemical through the skin. 
3.2.4 PSORIASIS 
Definition: 
A common, chronic, disfiguring, inflammatory and proliferative condition of the skin. 
The most characteristic lesions consist of red, scaly, sharply demarcated, indurated 
plaques, present particularly over extensor surfaces and scalp. 
Prevalence: 
Psoriasis is the most prevalent autoimmune disease. Psoriasis affects nearly 2- 3% of 
the world‟s population. In India, the incidence of psoriasis among total skin patients 
51 
 
ranged between 0.44 and 2.2%. The ratio of male to female is 2.46%.psoriasis often 
appears between the age of 15 and 25, but can develop at any age. Psoriatic arthritis 
usually develops between the ages of 30 and 50. The study also provided support for 
seasonal variation with 68% cases first diagnosed in winter & spring seasons. 60 
individuals per 100000 per year were seeking medical care for psoriasis for the first 
time. 
3.2.5 Aetiology: 
The cause of psoriasis is not fully understood, but medical world believe psoriasis is 
the result of several factors including genetics, environmental factors and the immune 
system. Around one-third of the people with psoriasis report a family history of the 
disease. Most of the identified genes relate to the immune system, particularly the 
major histocompatibility complex (MHC) and T cells. Classic genome wide linkage 
analysis has identifies nine loci on different chromosomes associated with psoriasis. 
They are called psoriasis susceptibility through a (PSORS1 through PSORS9). Three 
genes in PSORS1 locus have a strong association with psoriasis vulgaris.  
 HLA-C variant HLA-CW6 
 CDSN 
 CCHCR1 
T cells are involved in inflammatory process that leads to psoriasis. Psoriasis is an 
autoimmune condition. T cells mistakenly attack the skin cells. The attacks on the 
skin cause red, inflamed areas of the skin to develop. Psoriasis might be worse in the 
winter, dry air, less natural sunlight and cold temperatures can make symptoms worse. 
Factors that may trigger psoriasis: 
 Infections such as streptococci throat or skin infections 
 Stress 
 Injury to the skin such as sunburn cut scrape 
 Smoking 
 Heavy alcohol consumption 
 Vitamin D deficiency 
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Certain medications including lithium which is prescribed for bipolar disorder, B-
blockers, antimalarial drugs, iodides. 
Common symptoms of psoriasis: 
 Red, raised, inflamed patches of skin 
 Whitish-silver scales or plaques on the red patches 
 Dry skin that may crack and bleed 
 Soreness around patches 
 Itching and burning sensations around patches 
 Thick, pitted nails 
 Painful, swollen joints 
3.2.6 Pathophysiology of psoriasis: 
The pathophysiology of psoriasis is multifactorial & involves epidermal hyper 
proliferation, abnormal differentiation of epidermal keratinocytes and inflammation 
with immunologic alteration in the skin. Hyper proliferation is characterized by 
increased DNA synthesis and a markedly decreased turnover rate of epidermis. 
Abnormal keratinocyte differentiation involves increased expression of keratins and a 
delay in expression of other keratins that are expressed in normally differentiating 
skin. Inflammation results from an infiltrate of neutrophils in the epidermis and 
superficial dermis and an infiltrate of T lymphocytes in the dermis with a 
predominance of CD8+cells. T cells, dendritic cells, macrophages and keratinocytes 
are critically involved in the pathogenesis of psoriasis. In the dermis of psoriasis 
lesions, there were significantly higher numbers of Th 17 cells. 
Genetic, autoimmune reaction, stress and medication 
 
Hyperactive of T cells 
 
Epidermis infiltration and keratinocyte proliferation 
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Deregulated inflammatory process 
 
Large production of various cytokines (interferon, interleukin-12) 
 
Superficial blood vessel dilated and vascular engorgement 
 
Epidermal hyperplasia and improper cell maturation 
 
Fails to release adequate lipids which lead to flaking, scaling presentation of psoriasis 
lesion 
 
Silver scaling of skin 
 
3.2.7 Types of psoriasis: 
Psoriasis is clinically classified in 2 groups 
A. Pustular psoriasis 
B. Non-pustular psoriasis 
Pustular psoriasis: 
i) Generalized pustular psoriasis 
ii) Impetigo herpetiformis 
iii) Localized pus psoriasis 
iv) Palmoplantar pustular psoriasis 
Non-pustular psoriasis: 
i) Psoriasis vulgaris 
ii) Guttate psoriasis 
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iii) Erythrodermic psoriasis 
iv) Palmoplantar psoriasis 
v) Psoriatic arthritis 
vi) Inverse psoriasis 
Pustular psoriasis: 
Generalized pustular psoriasis: 
 Rarely seen form of psoriasis that progresses with pustules 
 It is mostly frequently seen in young individuals 
 It can develop secondary to abrupt withdrawal of system in steroid treatment 
hypocalcaemia or irritant treatment. 
 It onsets suddenly on an erythematous background association with general 
symptoms such as high fever, lassitude, polyarthralgia 
Impetigo herpetiformis: 
 Also known as generalized pustular psoriasis of pregnancy 
 It is characterized by erythematous lesions covered with pustules, which start 
and radiate from flexural regions. 
 It may be seen in the last trimester of pregnancy or during puerperal period 
 During its course, involvement of mucous membranes, onycholysis secondary 
to subungual pustules can be seen 
 General health symptoms of lassitude, fever, shivering, nausea and vomiting 
may be present. 
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Figure 3.2.2 Impetigo herpetiformis 
Localized pustular psoriasis: 
Palmoplantar pustular psoriasis: 
 It is a chronic recurrent form more frequently seen in women and those with a 
family history of palmoplantar pusulosis 
 It is 2-4 mm sized pustules localized on palmoplantar region 
 Smoking, tonsillitis, humidity and high temperature may activate the disease 
 
Figure 3.2.3 Palmoplantar pustular psoriasis 
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Non-pustular psoriasis: 
Psoriasis vulgaris: 
 The most frequently seen clinical form of psoriasis 
 It is observed as erythematous plaques with sharp boundaries and covered 
with pearlescent squamae. 
 Lesions demonstrate symmetric distribution they are localized on knees, 
elbows, scalp and sacral region. 
 In the surface of psoriasis plaque is scraped with a burn scalpel, squamae fall 
off as layers of white lamellae that exhibit coherence after removal, much like 
candle wax. 
 
Figure 3.2.4 Psoriasis vulgaris 
Guttate psoriasis: 
 This type is frequently seen in children and young adults 
 Lesions onset suddenly with an appearance like small droplets and less 
frequently as squamous psoriasis papules 
 It is generally manifesting after streptococcal infections 
 This form of psoriasis is most frequently associated with HLA-CW6 gene 
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 Lesions are generally seen on the trunk, proximal part of extremities, face and 
scalp. 
 They generally regress with 3-4 months. Sometimes lesions enlarge and take 
the shape of psoriasis plaque 
 Often antistreptolysin titers are elevated 
 
Figure 3.2.5 Guttate psoriasis 
Erythrodermis psoriasis: 
 It is a generalized form, affect nearly 80% of the body surface 
 Erythematous lesions are seen, typical papules and plaques lose their 
characteristics features 
 Patients have hypothermis due to widespread vasodilatation 
 Desquamation may also lead to protein loss and related systemic problems 
such as edema of the lower extremities leads to cardiac, renal, hepatie failure 
 Most frequently, it develops as a complication of psoriasis vulgaris or it can 
onset independently as erythrodermic psoriasis 
 
Figure 3.2.6 Erythrodermis psoriasis 
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Palmoplantar psoriasis: 
 This type of psoriasis symmetrically involves palms of hands and soles of the 
feet 
 Thenar regions are more frequently affected than hypothenar region 
 Squamae are the predominant lesions. Thick squamae may give appearance of 
keratoderma. 
 
Figure 3.2.7 Palmoplantar psoriasis 
Psoraissi arthritis: 
 In 75% of patients with psoriasis, psoriasis onsets before appearance of 
arthritic symptoms, while in 15% of cases, skin lesions are seen concurrently 
with arthritis. 
 It is characterized by a form of inflammation of the skin and joints 
 The onset of psoriasis arthritis generally occurs in the fourth and fifth decades 
of life 
 
Figure 3.2.8 Psoriasis arthritis 
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 Symmetrical polyarthritis, asymmetric oligoarthritis, spondylitis, distal 
interphalangeal its are the types of psoriasis arthritis 
 The arthritis frequently involves the knees, ankles and joints in the feet. The 
inflamed joints become painful, stiff, swollen, hot and tender. 
Inverse psoriasis: 
 Psoriasis that is localized in skin folds is termed flexural or inverse psoriasis 
 Squamous lesions do not form due to friction & moisture in skin folds 
 Lesions manifest as bright, red, symmetric, infiltrative, fissured plaques 
 It is more frequently seen in obese individuals 
 
Figure 3.2.9 Inverse psoriasis 
Psoriasis in nails: 
 Finger & toe nails frequently involved 
 Nails become pitting, subungual hyperkeratosis, onycholysis, yellowish brown 
spots under the nail plate is seen 
3.2.8 Complications: 
a) Cancer: 
People with psoriasis have an increased risk of developing certain cancers, 
particularly nonmelanoma skin cancer, lymphoma, lung cancer. Small increase in 
cancer risk could be the result of psoriasis chronic inflammatory such as UV therapy 
and the use of immunosuppressive drugs could be linked to the cancer occurrence. 
b) Cardiovascular disease: 
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Patients with psoriasis are at increased risk of cardiovascular disease, especially those 
with severe disease at an early age. The inflammatory response observed in psoriasis 
leads to insulin resistance, oxidative stress, endothelial dysfunction and 
atherosclerosis development which culminate with acute myocardial infarction or 
CVA. 
c) Celiac disease: 
The autoimmune disorder causes damage to the small intestine when gluten is 
consumed. More than a third of people with psoriasis have elevated antibodies to 
gliadin in their blood. 
d) Liver disease: 
 
Patients with psoriasis may have an increased risk for developing nonalcoholic fatty 
liver disease, a condition where too much fat is stored in liver cells. The steatotic liver 
produces proinflammatory, cytokines basicallt CRP, interleukin-6 and decreases the 
production of adiponectin. This increases the risk of severe disease by inflammatory 
burden. 
e) Kidney disease: 
Severe psoriatic patients are likely to develop chronic kidney disease. The risk of 
chronic kidney disease linked to psoriasis increases with age. The different psoriasis 
treatments have on the risk of chronic kidney disease. Some potential cofounders such 
as diabetes, hypertension & use of nephrotoxic drugs may increase the risk of renal 
abnormality in psoriatic patients. 
f) Depression: 
Having psoriasis can lead to emotional issues, such as low self-esteem and depression. 
Proinflammatory cytokines such as interleukin-1 and Il-6 are elevated in both 
psoriasis and depression. An acytokine called TNF-alpha may affect the serotonin 
level that could lead to depression. 
3.2.9 Differential diagnosis: 
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i. Nunomular eczema: 
Nummular eczema also known as discoid eczema, is a chronic condition that causes 
coin shaped spots develop on the skin. These spots are often itchy, and may ooze clear 
fluid or become dry and crusty. The lesions frequently develop on the arms or legs. 
The skin around the lesions may be red, scaly or inflamed. It often appears after a skin 
injury such as burn, abrasion or insect bite. 
ii. Pityriasis rubra pilaris: 
It is a rare condition that causes an orange-red, scaly rash on the skin with thickening 
and scaling of the palms and soles. There are often small scaly bumps surrounding the 
hair follicles. Most patients with pityriasis rubra pilaris have very thick skin on the 
palms and soles called palmoplantar keratoderma. This can cause painful cracks in the 
skin and difficulty walking. In most cases, PRP is not inherited, and the cause is not 
known. In some people, PRP has autosomal dominant inheritance & may be caused 
by mutations in CARD 14 gene. 
iii. Mycosis fungoides: 
It is a rare form of T-cell lymphoma of the skin. The skin becomes infiltrated with 
plaques & nodules that are composed of lymphocytes. The exact cause is not known. 
Antigen persistence, retroviruses and exposure to cancer causing substances are 
mostly involved. The area affected is generalized itching. Red patches scattered over 
the skin of the trunk and the extremities appear. Scaling present over the patches. 
Lympha denitis may also develop. 
iv. Dermatitis herpetiformis: 
It is also known as Duhring‟s disease. It is a chronic autoimmune blistering skin 
condition, characterized by blisters, that is intensely itchy. It is a cutaneous 
manifestation of celiac disease. Visually distributed symmetrically on extensor 
surfaces. Because of the intense itching patients usually scratch, which may lead to 
the formation of crusts. Sometimes these symptoms of coeliac disease, which 
typically include abdominal pain, bloating, weight loss and fatigue. Symptoms are 
likely to disappear if gluten ingestion is avoided. 
v. Bowen’s disease: 
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It is a very early form of skin cancer. The main sign is a red, scaly patch on the skin. 
It can be considered as an intraepidermal form of squamous cell carcinoma. It is 
gradually enlarging, well demarcated red colored plaque with a n irregular border of 
surface crusting or scaling. Causes of Bowen‟s disease include solar damage, arsenic 
poisoning, immunosuppression therapy, viral infection (human papillomavirus), 
chronic skin injury. 
3.2.10 Investigations: 
 There is no constantly present laboratory abnormality in uncomplicated 
psoriasis. 
 In some patients erythrocyte sedimentation rate is unaffected. 
 Modest hyperuricaemia may be found and has been attributed to enhanced 
epidermopoesis. 
 Immunoglobulins are generally normal, but selective IgA deficiency and 
monoclonal IgG gammopathy are documented in asscociation with psoriasis. 
 Skin biopsy is to determine the exact type of psoriasis and to rule out other 
disorders. 
I. Auspitz sign: 
It refers to the bleeding that can occur when the surface of a scaling rash has been 
removed. This bleeding occurs due to the thinning of the epidermis. When the 
epidermis is thin, the dermis is in close contact with the scale. This causes multiple 
tiny dots of blood to form on surface of the skin. 
II. Candle greasy sign: 
The removal of the scales reveals the skin with a glossy grease like appearance in 
psoriasis. 
III. Koebner phenomenon: 
It describes skin lesions which appear at the site of injury. The formation of psoriatic 
lesions in uninvolved skin of psoriatic patients after cutaneous trauma. 
3.2.11 Treatment: 
Treatment for psoriasis is divided into three main types: 
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1) Topical treatments 
2) Photo therapy 
3) Systemic medications 
 
1) Topical treatments: 
Topical applications ointments and creams that apply to skin can effectively treat mild 
to moderate psoriasis. 
ii) Topical corticosteroids: 
These are the most frequently prescribed medications. They reduce inflammation and 
relieve itching, long term use or overuse of strong corticosteroids can cause thinning 
of the skin. 
ii) Vitamin D analogues: 
Synthetic forms of vitamin D slow skin growth. Calcipotrience calcitriol is a cream or 
solution containing vitamin D analogue that treats mild to moderate psoriasis. 
iii) Anthralin: 
This medication helps slow skin cell growth. Also remove scales and make skin 
smoother. 
iv) Topical retinoids: 
These are vitamin A derivatives that may decrease inflammation. Most common side 
effect is skin irritation. They also increase sensitivity to sunlight. 
v) Salicylic acid: 
It promotes sloughing of dead skin cells and reduces scaling. It is found in medicated 
shampoos and scalp solutions to scalp psoriasis. 
vi) Coal tar: 
Derived from coal, it reduces scaling, itching and inflammation. It can irritate the 
skin. 
2) Photo therapy: 
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This treatment uses natural or artificial ultraviolet light. The simplest and easiest form 
of photo therapy involves exposing your skin to controlled amounts of natural 
sunlight. Other forms of light therapy include the use of artificial ultraviolet A or B 
light. 
i) Sunlight: 
Exposure to ultraviolet rays in sunlight or artificial light slows skin cell turnover and 
reduces scaling and inflammation. Daily exposures to small amounts of sunlight may 
improve psoriasis, but intense sun exposure can worsen symptoms and cause skin 
damage. 
ii) UV B phototherapy: 
Controlled doses of UV B light from an artificial light source may improve the 
psoriasis symptoms. UV B phototherapy also called broadband UV B, can be used to 
treat single patches, widespread psoriasis and psoriasis that resists topical treatments. 
iii) Narrow band UV B phototherapy: 
Narrow band UV B phototherapy may be more effective than broadband UV B 
treatment. It is usually administered two or three times a week until the skin improves. 
iv) Goeckerman therapy: 
Combined UV B and coal tar treatment, which is known as Goeckerman treatment. 
v) Psoralen plus ultraviolet A (PUVA): 
This form of photochemotherapy involves taking a light-sensitizing medication before 
exposure to UV A light. UV A light penetrates deeper into the skin than does UV B 
light. 
vi) Excimer laser: 
This form of light therapy, used for mild to moderate psoriasis, treats only the 
involved skin without harming healthy skin. A controlled beam of UV B light is 
directed to the psoriasis plaques to control scaling and inflammation. More powerful 
UV B light is used. 
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3) Systemic medications: 
i) Retinoids: 
Related to vitamin A, this group of drugs may help if severe psoriasis that doesn‟t 
respond to other therapies. 
ii) Methotrexate: 
It helps psoriasis by decreasing the production of skin cells and suppressing 
inflammation. It may also slow the progression of psoriatic arthiritis. 
iii) Cyclosporine: 
It suppresses the immune system, but can only be taken short-term. 
iv) Other medications: 
Thioguanine, hydroxyurea, etanercept, infliximab, adalimumab, some drugs are given 
by injection. 
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4. MATERIALS & METHODS 
 
The Clinical study on Psoriasis was earned out in the Post graduate department 
of Sirappu Maruthuvam, Govt Siddha Medical College, and Palayamkottai. In this 
study 40 patients (who satisfy the inclusion criteria and exclusion criteria) were 
treated as OP and IP patients. 
4.1 Inclusion criteria: 
 Age : 15 -60 years  
 Sex : Both male and female  
 Silvery scaly patches  
 Coin shaped lesions  
 Scaling with (or) without Itching  
 Patients who are willing to give specimen of blood for the investigation 
wherever required.  
 Patient willing to sign the informed consent stating that he/she will 
consciously stick to the treatment but can OPD out of the trial of his/ her own 
conscious discretion.  
The detailed history was taken from the patient about 
The diagnosis was made by following Siddha diagnostic methods. Nilam, 
Kaalam, Poriyalaridhal, Pulanalarithal, Vinaadhal, Mukkutram, Udal Thathukal Nilai 
and Envagai Thervugal, and the diagnosis of Naadi nilai. 
4.2 Exclusion Criteria: 
 Evidence of any skin condition other than psoriasis  
4.3 Assessment of Psoriasis with Symptoms: 
Severe - Marked plaque elevation, Scaling (present / not present), erythema 
Moderate - Moderate plaque elevation, Scaling (present / not present), erythema 
Mild - Slight plaque elevation, Scaling (present / not present), erythema 
Almost Clear - Intermediate between mild and clear.  
Clear - No signs of psoriasis. 
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4.4 Investigation: 
The following investigations were done in all selected patients in the 
laboratory at Government Siddha Medical College, Palayamkottai.  
4.5 Routine Investigation  
 Blood 
 Hb 
 ESR 
 Sugar-Fasting 
 Post prandial 
4.6 Renal functions tests: 
 a. Blood urea 
 b. Serum creatinine 
4.7 Liver function tests: 
 SGOT    
 SGPT 
 Alk.Phosphatase 
 Albumin 
 Globulin 
 Total Protein 
 Serum Bilirubin: Total, Direct, Indirect 
4.8 Urine 
 Albumin 
 Sugar 
 Deposits 
4.9 Investigation Based On Siddha System: 
1. Naa 
2. Niram 
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3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram - Neerkkuri, Neikkuri.  
7. Sparisam  
8. Naadi  
4.10 Skin examination: 
 Site 
 Colour 
 Size 
 Shape 
 Border  
4.11 Treatment: 
Vellai ennai 15ml at morning with hot water was given on the first day of 
treatment. All the patients were treated with the following medicines. 
4.12 Medicine Name:  
Internal Medicine                 : KOTTAI KARANTHAI CHOORANAM  
Reference    : GunapadamMooligai, Part I Pg. 226 
Dose     : 4gm, twice a day  
Adjuvant   : Hot water  
Duration    : 30 to 40 days   
External Medicine  : SEMPARUTHI POO ENNAI 
Reference                                   : The pharmacopoeia of Siddha Research 
medicines, Pg. No.: 117 
All the patients were advised to follow dietary regimen (or) Pathiyam. 
Pranayama and simple Yogasana were advised as a supportive therapy. The Bio - 
Chemical analysis was done in the department of Bio Chemistry, GSMCH 
70 
 
Palayamkottai. The Pharmacological analysis was done in the Pharmacological 
laboratory, Arulmigu Kalasalingam College of Pharmacy, Srivilliputhur.  
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5. OBSERVATION AND RESULTS 
 For the clinical study, 40 patients were selected and treated in PG III Sirappu 
Mruthuvam department, GSMC hospital, Palayamkottai.  Results were observed with 
respect to the following criteria, 
1. Gender distribution 
2. Family history 
3. Age distribution 
4. Kalam distribution 
5. Occupational distribution 
6. Seasonal variation 
7. Thinai 
8. Socio-economic status 
9. Dietary habits 
10. Precipitating factors 
11. Mode of onset 
12. Clinical features 
13. Other general clinical features 
14. Disturbances of kanmenthirium 
15. Derangement of vatham 
16. Disburbances of pitham 
17. Derangement of kabam 
18. Udal kattukal 
19. Envagai thervugal 
20. Selection of patients 
21. Effect of  therapy with trial drug alone 
22. Effect of therapy with trial drug along with complementary therapy  
23. Comparison between effective of trial drug and trial drug with complementary 
therapies. 
24. Overall results after treatment. 
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Table 5.1 Gender Distribution 
Sl. No Gender No. of Cases Percentage (%) 
1 Male 24 60 
2. Female 16 40 
 Total 40 100 
 
 
Figure 5.1 Gender Distributions (%) 
Inference 
About 60% of them were male and 40% of them were women 
 
Table 5.2 Family History 
Sl. No. Criteria No. of Cases Percentage (%) 
1 Family history (+ive) 4 10 
2. Family history (-ive) 36 90 
Total 40 100 
 
60% 
40% 
Male
Female
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Figure 5.2 Family History 
Inference 
About 10 % of them had positive family history 
 
Table 5.3 Age Distribution 
Sl. No. Age (Years) No. of Cases Percentage (%) 
1 15 – 25 3 7.5 
2. 25 – 35 4 10 
3 35 – 45 7 17.5 
4. 45 - 60 24 60 
5 Above 60 2 5 
 Total 40 100 
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Figure 5.3 Age Distribution 
Inference 
 The prevalence of the disease was found to be higher in the age group 45 - 60 
years. 
In siddha literature human life has been divided into three periods as follows 
1. Vadham 
2. Pitham 
3. Kabam 
The duration of each period is said to be 33 years. 
Table 5.4 Kalam Distribution 
Sl. No. Kalam No. of Cases Percentage (%) 
1 Vadha 6 15 
2 Pitha 34 85 
3 Kabha 0 0 
Total 40 100 
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Figure 5.4 Kalam Distribution 
Inference: 
 Out of 40 patients, 34 patients reported in Pitha kalam, 6 were in Vadha kalam 
and 0 patients in Kabha kalam. 
 
Table 5.5 Occupational Status 
Sl. No. Occupation No. of Cases Percentage (%) 
1 Farmer 8 20 
2. Business 8 20 
3 Home maker 9 22.5 
4. Manual labour 10 25 
5. Teacher 2 5 
6. Students 3 7.5 
Total 40 100 
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Figure 5.5 Occupational Status 
Inference  
 Out of 40 cases, in this study the rate of incidence is higher in manual labor 
(25%). 
Table 5.6 Seasonal Variations 
Sl. No. Seasons No. of Cases Percentage (%) 
1 Kaarkaalam (16 Aug – 15 Oct) 
 
3 7.5 
2. Koothirkaalam (16 Oct- 15 Dec) 
 
3 7.5 
3. Mupanikaalam (16 Dec - 15Feb) 
 
12 30 
4. Pinpani kaalam (16 Feb –  15 Apr) 7 17.5 
5. Ilavenirkaalam (16 Apr- 15 Jun) 5 12.5 
6. Muthuvenilkaalam (16 Jan –  15Aug) 9 22.5 
Total 40 100 
 
7.5 7.5 
30 
17.5 
12.5 
0
5
10
15
20
25
30
35
P
e
rc
e
n
ta
ge
 (
%
) 
Occupation 
78 
 
 
Figure 5.6 Seasonal Variations 
Inference 
  Out of 40 patients, 12 cases (30%) were admitted in Munpanikalam, 9 patients 
(22.5%) were admitted in muthuvenilkalam, 7 patients (17.5%) were admitted in 
pinpanikalam. Subsequently, 5 cases (12.5%) were admitted in illavenirkaalam and 3 
cases (7.5%) admitted in kaarkaalam and koothirkalam. 
Table 5.7 Thinai 
Sl. No. Thinai No. of Cases Percentage (%) 
1 Kurinji (Hill area) 0 0 
2 Mullai (Forest area) 0 0 
3 Marutham (Fertile land) 38 95 
4 Neithal (Coastal area) 2 5 
5 Palai (Desert land) 0 0 
Total 40 100 
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Figure 5.7 Thinai 
Inference 
 Among the 40 patients, 38 (95%) cases were from marutham and 2 (5%) cases 
were from Neithal thinai. 
 
Table 5.8 Socio Economic Status 
Sl. No. Socio economic status No. of Cases Percentage (%) 
1 Poor 8 20 
2 Middle class 26 65 
3 Rich 6 15 
Total 40 100 
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Figure 5.8 Socio Economic Status 
Inference 
About 65 % of the cases were from middle class socio economic status. 
 
Table 5.9 Dietary Habits 
Sl. No. Dietary habits No. of Cases Percentage (%) 
1 Vegetarian 3 7.5 
2 Mixed diet 37 92.5 
Total 40 100 
 
20 
65 
15 
0
10
20
30
40
50
60
70
Poor Middle class Rich
P
er
ce
n
ta
g
e 
(%
) 
Socio Economic Status 
81 
 
 
Figure 5.9 Dietary Habits 
Inference 
Out of all the cases only 3 patients were found to have mixed diet.  
 
Table 5.10 Precipitating Factors 
Sl. No. Precipitating factor No. of Cases Percentage (%) 
1 Skin Injury 2 5 
2 Infection 3 7.5 
3 Reaction to certain medicine 1 2.5 
4 Psychomatic 7 17.5 
5 Alcohol 6 15 
6 Smoking 14 35 
7 Unknown 7 17.5 
Total 40 100 
 
7.5 
92.5 
0
10
20
30
40
50
60
70
80
90
100
Vegetarian Mixed diet
P
e
rc
e
n
ta
ge
 (
%
) 
 
Dietery Habits 
82 
 
 
Figure 5.10 Precipitating Factors 
Inference 
 Among the 40 patients, 14 of them (35%) were unknown, 7 of them (17.5%) 
had the psychomatic disorders and 7 (17.5%) cases caused by smoking, 6 of them 
(15%) were alcoholic. 
 
Table 5.11 Mode of Onset 
Sl. No. Mode of Onset No. of Cases Percentage (%) 
1 Acute 4 10 
2. Chronic 36 90 
Total 40 100 
 
5 
7.5 
2.5 
17.5 
15 
35 
17.5 
0
5
10
15
20
25
30
35
40
P
er
ce
n
ta
g
e 
(%
) 
Participating Factors 
83 
 
 
Figure 5.11 Mode of Onset 
Inference 
According to this study 10% of cases were regarded as acute onset and 
remaining 90% of cases as chronic onset. 
 
Table 5.12 Clinical Features 
Sl. No. Clinical features No. of Cases Percentage (%) 
1 Red patches with silvory scaling 40 100 
2 Scalp lesions 24 60 
3 Auspitz sign 40 100 
4 Koebner‟s phenomenon 40 100 
5 Nai changes 8 20 
6 Palm and sole lesions 8 20 
7 Joint involvement 22 55 
8 Itching 34 85 
9 Candle grease sign 14 35 
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Figure 5.12 Clinical Features 
Inference 
 Among the forty cases all of them had scaling, itching, positive auspitz sign, 
koebher‟s phenomenon, 34 patients had itching, 22 patients had joint involvement, 8 
of them had nail changes, 14 of them had candle grease sign, 24 of them had scalp 
lesion and 8 of them had both palm & sole lesions. 
 
Table 5.13 General Clinical Features 
Sl. No. 
No. 
Clinical features No. of Cases Percentage (%) 
1 Constipation 16 40 
2 Eye sight problems 1 2.5 
3 Cough 2 5 
4 Insomnia 17 42.5 
5 Anemia 4 10 
6 Epigastric pain 0 0 
Total 40 100 
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Figure 5.13 General Clinical Features 
Inference 
 Among 40 patients, 17 had sleep disturbances (Insomnia), 16 of them had 
constipations, 4 of them had anemia, 2 of them had cough and 2 of them had eye sight 
problems. 
 
Table 5.14 Disturbances of Kanmenthirium 
Sl. No. Kanmenthirium No. of Cases Percentage (%) 
1 Vaai 0 0 
2 Kai 12 30 
3 Kaal 14 35 
4 Eruvai 16 40 
5 Karuvai 0 0 
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Figure 5.14 Disturbances of Kanmenthirium 
Inference 
 Among the all the kanmenthirium (kai, kaal, vaai, eruvai, karuvai) Kaal was 
affected for 13 patients (32.5%) and eruvai was affected in 7 cases (17.5%) and kai 
was affected in 15 cases (37.5%). 
 
Table 5.15 Derangement of Vatham 
Sl. No. Vatham Number of cases Percentage (%) 
1. Praanan 0 0 
2. Abaanan 16 40 
3. Viyaanan 40 100 
4. Udhaanan 0 0 
5. Samaanan 40 100 
6. Naagan 0 0 
7. Koorman 0 0 
8. Kirukaran 8 20 
9. Dhevathathan 30 75 
10. Dhananjeyan 0 0 
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Figure 5.15 Derangement of Vatham 
Inference 
 Among the vadham, 100% of them were affected by viyanan and samanan, 
75% of them were affected by devathathan, 40% of them were affected abanan and 
20% of them were affected by kirukaran.  
 
Table 5.16 Disturbances in Pitham 
Sl. No. Pitham Number of cases Percentage (%) 
1. Analpitham 0 0 
2. Ranjaga pitham 40 100 
3. Saathagam 40 100 
4. Prasagam 40 100 
5. Alosagam 0 0 
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Figure 5.16 Disturbances in Pitham 
Inference 
 Except Analpitham and Alosagam, all the other three Ranjagapitham, 
saathagam and prasagam were affected in all the cases. 
 
Table 5.17 Derangement of Kabham 
Sl. No. Kabham Number of cases Percentage (%) 
1. Avalambagam 12 30 
2. Kilethagam 0 0 
3. Pothagam 0 0 
4. Tharpagam 0 0 
5. Santhigam 22 55 
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Figure 5.17 Disturbances of Kabam 
Inference 
 Avalambagam was affected in 12 cases and Santhigam was affected in 22 
cases. 
 
Table 5.18 Condition of Udal Kattukal 
Sl. No. Udal kattukal NUMBER OF CASES PERCENTAGE (%) 
1 Saaram 40 100 
2 Senner 40 100 
3 Oon 0 0 
4 Kozhuppu 6 15 
5 Enbu 4 10 
6 Moolai 0 0 
7 Sukkilam 0 0 
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Table 5.18 Condition of Udal Kattukal 
Inference 
 Out of all the cases, Saaram and senneer were affected (100%), kozhuppu 
affected in 6 (15%) cases and enbu affected in 4 (10%) cases. 
 
Table 5.19 Envagaithervugal 
Sl. No. Envagai thervugal Number of cases Percentage (%) 
1. Sparisam 40 100 
2. Naa 0 0 
3. Niram 40 100 
4. Mozhi 0 0 
5. Vizhi 0 0 
6. Malam 16 40 
7. Moothiram 0 0 
8. Naadi 40 100 
 
 
Naadi :  Pitha vatham 14 cases (35%) 
  Vathapitham 16 cases (40%) 
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  Pithakabam 10 cases (25%)   
 
Figure 5.19 Envagaithervugal 
Inference 
 Sparisam and niram were affected in all the 40 cases (100%) and malam was 
affected in all 16 cases (40%).  
 
Table 5.20 After Treatment Results Overall 
Sl. No. Effect of Therapy No. of patients Percentage (%) 
1 Good improvement 28 70 
2 Moderate improvement 6 15 
3 Mild improvement 4 10 
4 No improvement 2 5 
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Figure 5.20 After Treatment Results Overall 
Inference 
 Out of 40 patients considered for the study, good improvement was observed 
in 70% patients, moderate improvement was observed in 15% patients, mild 
improvement was observed in 10% patients and no improvement was observed in 5% 
patients. 
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Table 5.1 List of Out Patients & In Patients of PG-III Sirappu Maruthuvam Department 
1. Kottaikaranthai Chooranam – Internal, 2. Semparuthi Poo Ennai - External 
Sl. 
NO. 
OP. NO. 
/ IP. 
NO. 
 
OP / 
IP 
NAME 
AGE / 
SEX 
OCCUPATION 
DATE OF 
ADMISSIO
N 
DATE OF 
DISCHAR
GE 
TOTAL 
NO. OF 
DAYS 
 
GRAD
E 
RESULTS 
1 47593 OP Subramani 15 / M Student 2.6.18 13.7.18 42 I GOOD 
2 47928 OP Santhanamari 42 / M 
Manual labour 
(Building) 
2.6.18 13.7.18 42 III MILD 
3 48565 OP Veerasami 42 / M 
Manual labour 
(Driver) 
6.6.18 19.7.18 45 I GOOD 
4 49655 OP Chandra 45 / F Home maker 11.6.18 19.7.18 39 II MODERATE 
5 49656 OP Vidhiya 21 / F Student 11.6.18 19.7.18 39 II MODERATE 
6 51668 OP Utchimagali 60 / M 
Manual labour 
(Driver) 
18.6.18 6.8.18 50 II MODERATE 
7 51754 OP Raja 60 / M 
Manual labour 
(Hospital staff) 
19.6.18 31.7.18 43 I GOOD 
8 52871 OP Kalliyammal 31 / F 
Manual labour 
(Tailor) 
22.6.18 16.8.18 56 I GOOD 
9 54674 OP Kailasam 60 / M Manual labour 29.6.18 3.8.18 36 I GOOD 
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(Accountant) 
10 54864 OP Murugan 56 / M Farmer 29.6.18 3.8.18 36 I GOOD 
11 54954 OP Sundar raj 35 / M 
Manual labour 
(Windmill) 
30.6.18 10.8.18 42 II MODERATE 
12 1684 IP Karuppasamy 60 / M farmer 2.7.18 31.7.18 30 I GOOD 
13 1694 IP Chandrasekar 54 / M Business 3.7.18 23.7.18 21 III MILD 
14 61578 OP Chellavadivu 54 / F Home Maker 24.7.18 6.9.18 45 I GOOD 
15 62076 OP 
Sivasubramani
an 
53 / M Business 26.7.18 6.9.18 43 I GOOD 
16 79681 OP Issaki Aachari 60 / M 
Manual labour 
(accountant) 
16.8.18 25.9.18 41 I GOOD 
17 68330 OP Saraswathi 60 / F Home Maker 17.8.18 17.9.18 32 I GOOD 
18 70623 OP Prema 46 / F Business 25.8.18 22.9.18 29 I GOOD 
19 2906 IP 
Balasubramani
an 
38 / M Farmer 28.11.18 6.1.19 40 I GOOD 
20 102145 OP Rahuman 49 / M Business 10.12.18 2.2.19 55 IV NO 
21 102669 OP Kaarthiga 24 / F Home Maker 11.12.18 5.2.19 57 IIII MILD 
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22 104691 OP Gurusamy 60 / M Business 18.12.18 7.2.19 52 I GOOD 
23 107385 OP Raja 42 / M Business 27.12.18 28.1.19 33 I GOOD 
24 944 OP Chandrasekar 60 / M 
Manual labour 
(accountant) 
3.1.19 8.2.19 37 I GOOD 
25 4791 OP Charles 47 / M Farmer 11.1.19 18.2.19 31 I GOOD 
26 7689 OP Iyappan 45 / M Farmer 21.1.19 1.3.19 40 III MILD 
27 9114 OP Petchiyammal 18 / F Student 24.1.19 1.3.19 37 I GOOD 
28 9524 OP Joylimonce 53 / F Teacher 25.1.19 2.3.19 37 I GOOD 
29 4835 OP Renganathan 35 / M Farmer 1.2.19 12.3.19 40 I GOOD 
30 13652 OP Jeyalakshmi 50 / F Business 6.2.19 6.3.19 29 I GOOD 
31 13508 OP Mayandi 70 / M Farmer 6.2.19 18.3.19 41 I GOOD 
32 15288 OP Bhagavathi 60 / F Farmer 11.2.19 18.3.19 36 I GOOD 
33 15848 OP Marriyammal 48 / F Home Maker 12.2.19 13.3.19 30 I GOOD 
34 17343 OP Ganapathy 50 / M Business 16.2.19 26.3.19 39 I GOOD 
35 19378 OP Thangaraj 48 / M Teacher 22.2.19 5.4.19 43 I GOOD 
36 19873 OP Muthulakshmi 52 / F Home maker 23.2.19 6.3.19 12 II MODERATE 
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37 19660 OP Vaellammal 60 / F Home maker 23.2.19 3.4.19 40 I GOOD 
38 19847 OP mahalakshmi 38 / F Home maker 23.2.19 6.4.19 43 II MODERATE 
39 608 IP Saraswathi 60 / F Home maker 8.3.19 2.4.19 26 I GOOD 
40 670 IP Udayaar pandi 60 / F Manual labour 14.3.19 15.4.19 33 II MODERATE 
 
Table 5.2 Blood Investigation of OP & IP Patients 
 
Sl. 
No. 
OP. No. / 
IP. No. 
WBC 
TOTAL 
WBC 
DIFFERENTIAL 
COUNT (DC) 
HB 
gms % 
E.S.R. (mm) BT AT 
BT AT 
BT AT BT AT BT AT 
B.S B.U CH S.C. B.S B.U CH S.C. 
P L E P L E 1hr 1hr ½hr 1hr ½hr 1hr 
1 47593 8100 8200 63 33 4 63 32 3 10.8 10.8 8 16 8 16 89 13 160 1.3 87 13 159 1.2 
2 47928 6800 6600 70 25 5 71 25 4 10.8 10.8 7 14 6 12 65 15 185 .6 66 13 154 .6 
3 48565 8000 8100 50 44 6 52 43 4 13 13 8 16 8 16 65 20 190 .6 64 21 180 .4 
4 49655 7000 8000 68 28 4 65 28 3 11 12 10 20 8 16 88 16 256 .8 86 17 240 .8 
5 49656 6800 6800 70 25 5 70 26 4 10.8 11 7 14 6 12 65 15 185 .6 65 18 184 .5 
6 51668 7000 7200 68 28 4 69 26 2 11 10.5 10 20 10 20 88 16 210 .8 89 16 200 .7 
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7 51754 6800 6700 59 36 5 58 36 3 12 13 31 62 15 30 94 20 179 .7 94 19 160 .8 
8 52871 7000 6400 68 28 4 65 24 2 9 10 6 12 7 14 88 16 189 .8 87 16 170 .7 
9 54674 7600 7500 65 30 5 64 30 4 13.2 14 6 12 3 9 122 45 180 1.2 120 42 178 ..8 
10 54864 8200 8300 50 40 6 52 40 4 13 12 8 16 4 12 82 20 189 .7 80 18 188 .7 
11 54954 8200 8400 52 40 6 51 41 4 13 12 8 16 6 12 82 20 189 .7 80 21 187 .6 
12 1684 (IP) 8500 8600 60 34 6 60 32 4 9.6 10 22 44 20 40 109 31 166 1.3 110 30 167 1.3 
13 1694 (IP) 8200 8400 71 24 5 60 25 5 12.2 12.6 15 35 15 30 72 27 220 .9 72 27 210 .9 
14 61578 5700 5500 60 37 4 61 37 5 12 13 10 20 10 20 94 19 162 1.2 94 20 160 1.1 
15 62076 5900 6000 60 37 3 60 38 3 11 11 10 20 8 16 94 18 162 1.2 93 18 160 1.2 
16 79681 8000 7800 50 44 6 48 43 5 13 13 8 16 8 16 65 20 190 .6 64 20 189 .6 
17 68330 7000 7000 56 39 5 55 38 4 10.9 11 31 62 15 30 94 20 208 .7 93 20 207 .7 
18 70623 7600 7800 65 32 3 64 33 3 12.1 12.1 22 44 10 20 149 19 213 1 148 18 213 1 
19 2906 (IP) 7600 7500 65 32 3 58 33 3 12 13 15 30 15 30 64 23 207 .8 65 20 200 .7 
20 102145 7500 7500 60 36 4 59 37 3 8.7 9 6 12 6 12 73 16 199 .6 72 16 199 .5 
21 102669 6200 6300 56 41 3 56 40 2 12.3 12 7.5 15 6 12 79 22 150 .8 76 22 148 .6 
22 104691 9200 9300 62 31 7 62 30 5 12.5 12 8 16 8 16 109 25 179 .8 105 24 178 .8 
23 107385 6800 6700 60 37 3 60 36 2 12 13 10 20 10 20 194 21 162 .8 192 20 163 .7 
24 944 8100 8200 46 49 5 50 48 4 12.4 13 10 20 8 16 150 20 155 1.1 148 19 150 .9 
25 4791 7200 7000 48 32 3 49 33 3 11 12 6 12 6 12 96 22 168 .8 94 21 166 .7 
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26 7689 8000 8100 46 49 5 47 49 4 12.4 12.6 5 10 4 8 150 20 155 1.1 145 19 154 .9 
27 9114 7200 7100 62 30 6 62 32 5 12.5 12.6 8 16 7 14 109 19 149 .8 105 18 178 .7 
28 9524 7300 7400 59 37 4 59 38 3 10.3 10.5 8 16 5 10 97 22 153 .9 96 22 152 .8 
29 4835 7000 7200 59 35 6 59 37 7 14.1 14 12 24 10 20 97 24 172 .4 97 24 171 .4 
30 13652 8300 8300 50 47 3 49 47 3 11.3 12 7.5 15 6 12 100 28 203 .9 98 28 200 .8 
31 13508 10100 10200 80 17 3 82 18 3 13.3 14 10 20 10 20 95 18 153 .6 92 18 153 .5 
32 15288 7500 7600 60 34 3 62 34 3 10.2 11 12 24 10 20 74 16 199 .6 72 15 196 .4 
33 15848 9400 9300 75 20 5 76 22 4 11.4 12 17.5 35 10 20 282 28 200 .7 260 28 198 .6 
34 17343 7300 7400 64 30 6 66 32 5 14.3 14 20 40 10 20 95 23 147 .8 94 22 145 .7 
35 19378 9600 9500 59 40 1 59 42 1 11.3 12 10 20 8 16 105 20 197 1 103 20 196 .9 
36 19873 7600 7800 64 30 6 66 30 4 14.3 14.5 10 20 10 20 95 23 147 .1 95 22 146 .1 
37 19660 9400 9600 75 20 5 76 22 4 11.4 12 17.5 35 10 20 92 26 179 .8 90 26 178 .7 
38 19847 7400 7400 61 36 3 61 37 3 11 11.6 10 20 10 20 80 47 187 .8 80 45 186 .6 
39 608 (IP) 7800 7600 61 36 3 60 38 2 10.1 11 10 20 8 16 98 26 132 .9 96 26 134 .8 
40 670 (IP) 7800 7800 58 35 7 58 36 7 10.2 10.8 7 15 6 12 80 47 193 1.3 82 45 189 1.2 
 
BT – Before Treatment, AT- After Treatment, ESR – Erythrocyte Sedimentation Rate, HB – Hemoglobin, BS – Blood sugar, BU- Blood urea 
SC – Serum creatinine, P - Polymorph, L - Lymphocytes, E – Eosinophils, CH – Cholesterol 
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Table 5.3 Urine Analysis of OP & IP Patients 
Sl. No. 
O.P. No. / IP 
No. 
IP / OP 
Albumin Sugar Deposit 
BT AT BT AT BT AT 
1 47593 OP NIL NIL NIL NIL NIL NIL 
2 47928 
OP NIL NIL NIL NIL Few pus cells NAD 
3 48565 
OP NIL NIL NIL NIL NAD NIL 
4 49655 
OP NIL NIL NIL NIL NIL NIL 
5 49656 
OP NIL NIL NIL NIL Few pus cells 
Few pus 
cells 
6 51668 
OP NIL NIL NIL NIL Few pus cells NAD 
7 51754 
OP NIL NIL NIL NIL Few pus cells 
Few pus 
cells 
8 52871 
OP NIL NIL NIL NIL Few pus cells NAD 
9 54674 
OP NIL NIL NIL NIL NIL NIL 
10 54864 
OP NIL NIL NIL NIL NIL NIL 
11 54954 
OP NIL NIL NIL NIL NIL NIL 
12 1684 IP NIL NIL NIL NIL NAD NAD 
100 
 
13 1694 IP NIL NIL NIL NIL NIL NIL 
14 61578 
OP NIL NIL NIL NIL Few pus cells NAD 
15 62076 
OP NIL NIL NIL NIL Few pus cells NIL 
16 79681 
OP NIL NIL NIL NIL Few pus cells NAD 
17 68330 
OP NIL NIL NIL NIL NIL NIL 
18 70623 
OP NIL NIL NIL NIL Few pus cells NAD 
19 2906 IP NIL NIL NIL NIL NIL 
NIL 
20 102145 
OP NIL NIL NIL NIL Few pus cells NAD 
21 102669 
OP NIL NIL NIL NIL NIL NIL 
22 104691 
OP NIL NIL NIL NIL Few pus cells NIL 
23 107385 
OP NIL NIL NIL NIL Few pus cells NIL 
24 944 
OP NIL NIL NIL NIL 1-2 pus cells NAD 
25 4791 
OP NIL NIL NIL NIL NIL NIL 
26 7689 
OP NIL NIL NIL NIL 1-2 pus cells NAD 
27 9114 
OP NIL NIL NIL NIL Few pus cells NAD 
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28 9524 
OP NIL NIL NIL NIL NAD NAD 
29 4835 
OP NIL NIL NIL NIL 1-2 pus cells NAD 
30 13652 
OP NIL NIL NIL NIL Few pus cells NAD 
31 13508 
OP NIL NIL NIL NIL Few pus cells NIL 
32 15288 
OP NIL NIL NIL NIL Few pus cells NAD 
33 15848 
OP NIL NIL +++ ++ NAD NAD 
34 17343 
OP NIL NIL NIL NIL 2-4 pus cells NAD 
35 19378 
OP NIL NIL NIL NIL Few pus cells NAD 
36 19873 
OP NIL NIL NIL NIL 2-4 pus cells NAD 
37 19660 
OP NIL NIL NIL NIL Few pus cells NAD 
38 19847 
OP NIL NIL NIL NIL Few pus cells NAD 
39 608 
IP NIL NIL NIL NIL NAD NIL 
40 670 
IP NIL NIL NIL NIL Few pus cells NIL 
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DISCUSSION 
 
A Study on Kalanjapadai 
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6. DISCUSSION 
 A common, chronic, disfiguring, inflammatory and proliferative condition of 
the skin. The most characteristic lesions consist of red, scaly, sharply demarcated, 
indurated plaques, present particularly over extensor surfaces and scalp. 
 It can have a profound social impact of life difficulties in the work place, 
socialization with family members and friends, exclusion from public facilities and 
getting a job are some of the psycho social impact. 
 The major clinical features are itching, scaling, erythema, auspitz, sign with 
this background, the disease Psoriasis is taken for the study. 
 To gratifying the most important intend of this study, the trial drugs given 
below was used in treating the disease psoriasis.  They are 
1. Kottai karanthai chooranam as an internal medicine. 
2. Semparuthi poo ennai as an external medicine. 
  A thorough study of the disease psoriasis was done and it is correlated with 
signs and symptoms of psoriasis indicated in the siddha literatures. 
 To achieve the primary goal of this, a complete open clinical trial was done by 
treating the disease psoriasis with trial drugs. 
 The clinical appraisal was done as per the protocol and the data were collected 
by using prescribed forms. The disease psoriasis was studied under various criteria to 
full-fill secondary objective of the study and the results were pragmatic and tabulated. 
 The assorted criteria and the results were discussed here under. 
6.1. Gender distributions 
 Out of 40 cases, 24 cases were male and 16 were cases female. Hence it comes 
to interference that prevalence may be high in males.  However men reported 
greater due to work related stress. Hence it is correlated with research studies.  
(MADUKKAA GUPTA 2007 VOL 34 700-703). 
6.2. Age distribution 
 From the above study it came to know, the incidence of this disease is high in 
age group 45 to 60 when compared to other age groups.  
 Hence it infers, the result shown in my study is more or less equal to the 
global epidemiological studies.  Paris et al. (2012), Raval 10(2):189-96. 
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6.3. Kaalam distribution 
 From the above study, it infers that the disease is highly prevalent in pitha 
kaalam, when compared to other kaalams. 
6.4. Occupational status 
 From the above data it was clear that there was no connection between the 
occupational status and the Psoriasis incidence. 
 Luigi Naadi M.X et al (2007) also accepted the same result in his study. 
6.5. Dietary habits 
 Out of the 40 patients selected, among them 3 were non vegetarian and 37 of 
them were vegetarian. 
6.6. Seasonal variations 
 Among the 40 patients selected, the disease had occured in munpani kaalams 
when compared to other kaalams. It is evident from the book “Practice of 
dermatology”. 
 According to the above mentioned data 30% of cases came in munpanikaalam, 
22.5% cases muthuvenirkaalam. 
6.7. Thinai 
 From the above mentioned data, 38(95%) cases were from Marutham and 
2(5%) cases were from Neithal thinai. 
 Hence the disease was studied in single area not globally, so it is difficult to 
come to conclusion by this above data for evaluating the thinai distribution 
scientifically. 
6.8. Socio economic status 
 From the above data, 65% are from middle socio economic status, 20% were 
low and 15% belong to rich economic status. There are no accurate evidences for 
correlation between psoriasis and socio economic status but as per research evidences 
by exposure to antigenic surfaces result in higher prevalence of psoriasis. Therefore 
peoples from low socio economic status were easily exposed to antigenic exposure 
due to infection so they have high prevalence of psoriasis. 
6.9. Mode of onset 
From the above tabulation it shows that 90% of the cases were reported to 
have chronic onset and the remaining 10% were reported to have acute mode of onset.  
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6.10. Clinical features 
 According to this study, 85% of them had itching (which is correlated with the 
study and research by gerald kruegae Arch Decmatol 2001) and 55% of patients had 
joint involvement, 35% of them had candle grease sign and 20% had nail changes. 
Petty et.al.J AM Acad Decmatol 2003.  Radtke AM et.al.  This infers that joint 
involvement coincides with research studies. 
6.11. Disturbances in kanmenthiriums 
 Among 40 patients, eruvai have been affected in 16 cases, kaal have been 
affected in 14 cases and 12 cases affected in kai kanmenthirium. 
6.12. Distribution of three thodams 
6.12.1. Vadham 
 From the above tabulation, samanan, viyanan are pretentious in 100% of cases 
and abanan were affected in 40% of cases and uthanan were affected 20% of cases. 
6.12.2. Pitham 
 Ranjagam, Saathagam and Prasagam were affected in all 100% cases. 
 6.12.3. Kahbam 
 Santhigam was affected 22 cases and avalambagam are pretentious in 12 
cases. 
6.13. Udal kattugal 
 From the seven udal kattugal, saaram, seneer have been affected in all of the 
40 cases, enbu in 10% cases and kozhuppu have been affected 15% of cases. 
6.14. Envagai Thervugal 
 Among the 40 cases, sparisam, niram and naadi have been affected in all cases 
while malam have been affected in 16 patients. 
 In naadi, pitha vatham were present in 14 cases (35%), vadha pitham 16 were 
present in cases (40%) and vatha kabham were present in 10 cases (25%). 
6.15. Investigations 
 Laboratory investigations were done in all the cases before and after treatment. 
The significant variation occur in parameters like ESR and HB, while other 
parameters have insignificant variation. 
6.16. Pre-clinical studies 
 The biochemical study of kottai karanthai chooranam had revealed the 
presence of calcium, ferrous iron, sulphate, unsaturated compound, chloride and 
amino acid. 
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6.17. Pharmacological studies 
 The pharmacological studies done in kottai karanthai chooranam and 
semparuthi poo ennai revealed the presence of actions such as 
1. Anti-inflammatory action 
2. Anti-histamine action 
The pharmacological studies done in semparuthi poo ennai revealed that it has 
anti-inflammatory activity. 
6.18. Toxicity studies 
 Acute toxicity studies have done for kottai karanthai chooranam in rats and 
it is analyzed that they have no toxicity. 
6.19. Line of treatment 
 According to our humoral pathology, three dosham are deranged in all 
diseases.  Therefore the line of tretment starts with regularize the deranged vadham 
for psoriasis to normalize the deranged vadha kutram purgative had to be given. So 
the purgative vellai ennai – 15ml were given to all 40 patients while be beginning the 
treatment. 
 Next day trial drug kottai karanthai chooranam – 4g (Bd) was given along 
with semparuthi poo ennai (30ml) external medicine for a total of 40 patients i.e. 20 
OP and 20 IP.  
 While 5 IP patients trial drug along with complement therapy Pranayamam, 
asanas were given. 
 During the treatment period the patients are strictly advised to follow dietary 
regimen to overcome the adverse effect of trial drug given and also for earlier 
prognosis. 
6.20. Clinical outcome 
 The clinical outcome was assessed by signs of psoriasis (Auspitz sign, 
koebner‟s phenomenon, candle grease sign) plaques, itching, erythema, scaling and 
these are classified into four grades described above.  
According to that gradations 
1. 70% had Good improvement 
2. 15% had moderately improved 
3. 10% had mild improved and 
4. 5% had no improvement 
There is no adverse effect observed while giving the trial medicines. 
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7. SUMMARY 
 The disease psoriasis was reasonably studied with the disease kalanjaga padai 
with reference to its causes.  Pathogenesis and clinical features. 
 The aim of this study is to treat the illness and sufferings of Psoriasis. psoriasis 
is a common and distressing skin condition.  Importantly, it is not simply a cosmetic 
problem- even people with limited disease find the condition affect their everyday 
lives (stern Rs.et.al.2004-9(2) 136-39). 
 The trial medicines are prepared as per siddha literature. 
 The trial medicines were 
1. kottai karanthai chooranam 4g (Bd) 
2. semparuthi poo ennai 30ml (external) 
The trial drug was given to 40 patients, for 40 days.  The patients were selected 
based on inclusion and exclusion criteria. 
While starting the treatment routine blood analysis, urine analysis, kidney function 
test and liver function test were done.  Siddha methods like udal thathukkal, Envagai 
thervu, Neerkuri and Neikuri were noted in case sheet proforma. 
 Patients were instructed to come for next review once in 7 days. 
7.1. Age 
Most of the patients are from the age group (45-60) 
7.2. Thinai 
Most of the patients were from marutham thinai. 
7.3. Occupation 
The manual labours are mostly affected by Psoriasis. Stress is also a major 
triggering factor for Psoriasis. 
7.4. Diet and Physical habits 
Most of the patients were non vegetarians and smoke may also have a major 
impact on Psoriasis. 
7.5. Udal  kattugal 
From the seven udal kattugal, saaram, seneer have been affected in all of the 40 
cases, whereas enbu affected 10% of cases and kozhuppu have been affected with 
15% of cases. 
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7.6. Pre-clinical studies 
The pharmacological analysis of kottai karanthai chooranam shows that these 
medicines have 
1. Anti-inflammatory effect 
2. Anti-histaminic effect 
Result the clinical outcome was assessed by gradations. Hence the result shows that 
70% had good improvement. Particularly the results were marvelous when it is given 
trial drug along with complement therapies. 
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8. CONCLUSION 
KALANJAGAPADAI (PSORIASIS) is primarly due the derangement of 
vadham. The trial medicine “kottai karanthai chooranam” predominates with 
kaippu taste respectively neutralizes the vatham. 
 Preclinical studies show that these medicines have anti-inflammatory and anti-
histamine, effect. 
 The “kottai karanthai chooranam” do not produce any toxicity in preclinical 
study.  So it is not toxic and safe drug for psoriasis. 
 No contraindications were reported during the course of treatment. 
 The overall outcome of this disease is astounding. The clinical signs in this 
study were found to have 70% good improvement.  When trial medicines are given 
along with complement therapy were found to have wonderful effect compared to 
giving trial medicines alone. 
 Therefore the author concluded that the trial medicine “kottai karanthai 
chooranam” and semparuthi poo ennai is very positive remedy for “Kalanjagapadai”. 
8.1 ASSESSMENT OF RESULTS 
CLASSIFICATION OF PSORIASIS BASED ON THE SEVERITY OF 
SYMPTOMS 
8.1.1 SYMPTOM 
1 Severe marked plaque elevation, scaling and or crythema, affecting more 
than 10% of the body surface. 
2. Moderate Moderate plaque elevation, scaling and erythema /affecting 3-10% 
of the body surface 
3 Mild Slight plaque elevation, scaling and or erythema/affecting less than 
3% of the body surface. 
4 Clear No signs of psoriasis. 
- F Alzeni et al.(2011) 
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8.2 OVERALL RESULTS AFTER TREATMENT 
 Based on the outcome, all the 40 patients have been classified into 4 grades.  
The gradation is as follows, 
Grade I (Good Improvement) – No signs of psoriasis (Post inflammatory hyper 
pigmentation may be present). 
Grade II (Moderate improvement) – Slight plaque elevation reduction in size of all 
lesions, mild scaling.  Itching and/or erythema. 
Grade III (Mild Improvement) – No new lesions, moderate plaque elevation, 
scaling, Itching and/or erythema. 
Grade IV (No Improvement) – Very marked plaque elevation, scaling, Itching 
and/or erythema with or without new lesions. 
Patient Name: Subramani Age: 15 Sex: Male OP No.: 47593 
Before Treatment 
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After Treatment 
 
Patient Name: Sivasubramanian Age: 55 Sex: Male OP No.: 62076 
Before Treatment 
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After Treatment 
 
Patient Name: Raja Age: 42 Sex: Male OP No.: 107385 
Before Treatment 
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After Treatment 
 
Patient Name: Balasubramanian Age: 38 Sex: Male IP No.: 2906 
Before Treatment 
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After Treatment 
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9.1 ANNEXURE-I 
PREPARATION & PROPERTIES OF TRIAL DRUGS 
 
Standard operating procedure for preparation of kottai karanthai chooranam 
(Internal) and semparuthi poo ennai (External) 
9.1.1 Source of raw drugs: 
The required drugs for preparation of kottai karanthai chooranam (Internal) and 
semparuthi poo ennai (External) are collected from farms and some drugs are 
purchased from reputed local vendor. The raw drugs were authenticated by medical 
botanist of Government Siddha Medical College, Palayamkottai. The drugs are then 
purified and the medicines were prepared in the gunapadam laboratory of 
Government Siddha Medical College, Palayamkottai. 
9.1.2 Purification of internal medicine: 
9.1.2.1 Kottai karanthai: 
 Dried in shade (sarugu patham) 
 Powder form 
9.1.3 Preparation of trial drugs 
9.1.3.1 Internal medicine 
 Kottai karanthai chooranam 
Ingredients: 
 Kottai karanthai-Sphaeranthus indicus (35gm) 
Preparation: 
The above drug is purified and powdered into fine and coarse powdered form. 
Then it is filtered using pure white cloth. And the same is preserved it in an airtight 
container. 
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Dosage: 
 4 grams – morning and night 
Indication: 
It is indicated internally for psoriasis 
Drug storage: 
The trial drug is stored in clean dry air tight container and it is dispensed to 
patients in packets. 
 
 
Figure 9.1.1 Kottai karanthai (Internal Medicine) 
9.1.3.2 External medicine: 
 Semparuthi poo ennai 
Ingredients: 
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Figure 9.1.2 Semparuthi Poo 
 
 
 
Figure 9.1.3 Coconut Oil 
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Figure 9.1.4 Suraipattai 
 
 
 
Figure 9.1.5 Vaembadaipattai 
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Figure 9.1.6 Semparuthi Poo Ennai 
 Semparuthi poo – hibiscus rosasinensis – ¼ to ½ Kg 
 Coconut oil – cocus nucifera – 1 to 1.5 Kg 
 Surai pattai – ziziphus oenoplia – 17.5 grams 
 Vaempadampattai – ventilago maderaspatana – 17.5 gram 
Preparation: 
The flowers are kept soaked in the coconut oil for 10 to 20 days and then 
filtered. The drugs 3 and 4 are subjected to powdered form are then added to the 
filtered oil. Then it is exposed to the sun for 3 days and it decanted and preserved in a 
bottle. 
Indication: 
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It is indicated externally for psoriasis. 
 Drug usage: 
The trial drug is stored in a clean, dry, air tight container as narrow bottles. 
9.1.4 Properties of trial drugs 
9.1.4.1 Internal medicine: 
a) Kottai karanthai – தகாடற்ட க஧஢்ற஡ 
 Botanical name – spaeranthus indicus 
 Family – asteraceae 
 சுவப - வக஢்பு 
 ட஡்வண – மப஢்஢ண் 
 பி஥ிவு - கா஥஢்்பு 
 Part used – whole plant 
Action: 
 Alterative 
 Demulcent 
 Stomachic 
 Anthelmintic 
 Depurative 
 Refrigerant 
 Tonic 
கு஠஥்: 
“தகாடற்டக் க஧஢்ற஡஡றணக் கூோ஥ லு஠்ட஬஧க்்கு 
த஬டற்ட ஡஠ிம௅஥தி ச஥க஥் சதா஢் – துட்டே ்
தோறி சி஧ங்கு ஬ண்க஧த்தாண் சநாந்நாது ஢ாளூ஥் 
஥றி஥னமு஢் ஡ாணிநங்கு ஥ான்” 
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விபக்க஥்: 
இட஡ா஧், ஑ளுக்கு மபந்வந, க஥஢்஢ா஡், மசாறி, சி஥ங்கு இவப 
தீருபட஧்஧ாண஧், ணறி஢஝்஝ ஏருவுங்கநிவுண் நணலுண் பநி, மசாறி, 
சிவ஡஢்பு ப௅டலிதவபப௉ண் ஒழிப௉ண் நடா஦்பிஞிப௉ண் ந஢ாண் 
Chemical constituents: 
Flower heads: 
 3 eudesmanolides 
 11α, 13 dihydro 3α, 7α - dihydroxyfrullanolide 
 11α, 13 dihydro 7α, 13 - dihydroxyfrullanolide 
 11α, 13 dihydroxy - 7α – hydroxyl – 13 methoxyfrullanolide 
Whole plant contains: 
 Shgmasterol 
 Β-sitosterol 
 Sesquiterpene lactone 
 Sesquiterpine glycoside 
 Sphaeranthanolide 
 Aerial part contains: 
 7α-eudesmanolide 
 Sphaeranthine 
 5 hydroxy-7-methoxy-b-c-glycosylflavone 
 Hentriacontane 
Therapeutic uses: 
 Powder form of dried flowers of sphaeranthus indicus act as a coolant 
 Take half teaspoon powdered root of sphaeranthus indicus. It helps in 
expulsion of intestinal worms 
 Powder the dried leaves of sphaeranthus indicus, to skin diseases 
 Grind dried sphaeranthus indicusplant. Add little water and apply on the 
affected part in syphilitic ulcer 
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Pharmacological activity: 
 Immunomodulatory activity 
 Antioxidant activity 
 Anti-inflammatory activity 
 Analgesic activity 
 Antihyperglycemic activity 
 Hepatoprotective activity 
 Antimicrobial activity 
 Antihyperlipidemic activity 
 Neuroleptic activity 
9.1.4.2 External medicine: 
a) தே஥்தமே஡்தி பூ – semparuthi poo 
 Botanical name: Hibiscus rosa sinensis 
 Family: malvaceae 
 சுவப – இ஡ி஢்பு 
 ட஡்வண – ட஝்஢ண் 
 பி஥ிவு - இ஡ி஢்பு 
Parts used:  
 Leaf 
 Flower 
 Root 
Action: 
 Laxative 
 Aphrodisiac 
 Emmenagogue 
 Emollient 
 Demulcent 
 Refrigerant 
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கு஠஥்: 
“தே஥்த஧஡்ற஡ ச஥கத஬டற்ட தீ஧ாத் பி஧ப௃த஦ாடு 
஬஥்பி஧஡்஡ த஬ப்றப ஬஫஬஫த்பு஥் – த஬஥்பு஥் 
ததமே஥்தாடு ஧஡்஡பி஡்஡ சத஡஥் அகந்று஥் 
கமே஥்தா த஥ாழி஥ம௃சன! கா஠்”. 
விபக்க஥்: 
இட஡ா஧் மபந்வந, குருதிமபந்வந, ம஢ருண்஢ாடு, குருதிதன஧் 
ந஠ாத் இவப ஠ீங்குண். 
Chemical constituents: 
 It contains tannins, anthraquinones, quinines, phenols, flavanoides, alkaloids, 
terpenoids saponins, cardiac glycosides, mucilage, steroids, essential oils 
 Cyclopropanoids methylsterculate methyl-2-hydroxy sterculate malvalate β-
sitosterol 
The major anthocyanin in the flower: 
 Cyaniding 3-sophoroside 
 The flowers contained 4 types of flavonoids: 
 Rutin 
 Quercetin 
 Kaempterol 
 Myricetin 
Pharmacological activity: 
 Antioxidant 
 Anti-inflammatory 
 Antipyretic 
 Analgesic 
 Immune modulatory 
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 Antimicrobial activity 
 Dermatological activity 
 Anti haemolytic activity 
 Antidiabetic activity 
b) ச஡ங்கா஦் ஋஠்த஠஦் – coconut oil 
 Botanical name: cocus nucifera 
 Family: arecaceae 
 சுவப – இ஡ி஢்பு 
 ட஡்வண – ட஝்஢ண் 
 பி஥ிவு - இ஡ி஢்பு 
Action: 
 Nutritive 
 Refrigerant 
 Diuretic 
 Demulcent 
 Laxative 
Chemical constituents: 
a. Saturated fatty acids: 
 Lauric acid 
 Myristic acid 
 Caprylic acid 
 Caproic acid 
 Stearic acid 
 Palmitic acid 
 Vitamins: 
 Vitamin E 
 Vitamin K 
b. Unsaturated fatty acids: 
 Oleic acid 
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 Linoleic acid 
 Linolenic acid 
Pharmacological activity: 
 Antihelminthic 
 Anti-inflammatory 
 Antioxidant 
 Antifungal 
 Antimicrobial 
 Antitumor activity 
Medicinal uses of coconut oil: 
 Coconut oil raises HDL cholesterol and lower risk of heart disease 
 It can be used as a skin moisturizer because of its vitamin E content and its 
antioxidant action in the body 
 Coconut oil has lauric acid, it contains antifungal, antiviral, anti bacterial 
properties. 
 It makes hair shinier, stronger because it penetrates better than other oils. 
c) சூற஧த்தடற்ட: suraipattai 
 Botanical name: ziziphus oenoplia 
 Family: Rhamnaeae 
 சுவப – இ஡ி஢்பு 
 ட஡்வண – ட஝்஢ண் 
 பி஥ிவு - இ஡ி஢்பு 
Action: 
 Aphrodisiac 
 Nutritive 
கு஠஥்: 
“஥஢்஡஥் அதிக஧ிக்கு஥் ஬ண்சீ஡பசேமே஥் 
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உ஢்து குடன்஬லிம௅஥் உ஠்டாங்கா஠் – மு஢்து஢வின் 
காற஧த் த஫஡்தின் சுதி஡்஡்த஡ாமே சத஡மு஥ாஞ் 
சூற஧த் த஫஡்திந்குே ்தோன்” 
விபக்க஥்: 
இட஡ா஧் ண஠்டண், ஐதம஢ருக்கு, கு஝பலி உஞ்஝ாகுண். 
 Chemical constituents: 
a. Bark:  
 β-sitosterol 
 Β-sitosteryl-β-D-glycoside 
 Luteolin 
 Quercetin 
Pharmacological activity: 
 Woundhealing activity 
 Anti microbial activity 
 Anti-analgesic activity 
 Immunomodulator effect 
 Anthelmintic activity 
 Antioxidant activity 
d) ச஬஥்தாட஥்தடற்ட: vaempadampattai 
Botanical name: ventilago maderaspatana 
 Family: rhamnaceae 
 சுவப – இ஡ி஢்பு 
 ட஡்வண – ட஝்஢ண் 
 பி஥ிவு - இ஡ி஢்பு 
Action: 
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 Carminative 
 Astringent 
 Stomachic 
Pharmacological activity: 
 Anti-microbial and anti-bacterial activity 
 Anti-inflamatory activity 
 Antioxidant activity 
 Antidiabetic activity 
 Hepatoprotective activity 
Therapeutic uses: 
 The powder of stem bark mixed with gingerly oil is applied externally to treat 
skin diseases. 
 The bark paste of this plant is used in the treatment of bone fracture 
 Latex of this plant is used to cure oedema 
 Tender branches of this plant is used to treat vertigo 
 Seeds mixed with milk or water has showed anti-diabetic activity 
Chemical constituents: 
 Root bark shows secondary metabolites such as various anthraquinones, 
including ventione A & B, chrysophanol, physcion, emodin, islandicin, 
xanthorin and xanthorin – 5 – methyl ether. 
 Benziso-chromanquinones, ventilaquinones A, B, C, D, E, F, G & H 
 Whole plant contains isofurano naphthaquinones,ventilone – C, 
ventiloquinones E and G, Jelenthrin  
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9.2 ANNEXURE – II 
BIO-CHEMICAL ANALYSIS 
BIOCHEMICAL ANALYSIS OF MONOHERBAL DRUG KOTTAI 
KARANTHAI CHOORANAM 
Preparation of extract: 
5 grams of the drug is accurately weighed and placed in a 250ml clean beaker. 
Dissolve the drug using 50ml of distilled water and bring it to boil for about 10 
minutes. Allow it to cool and filter out into a 100ml volumetric flask. Bring the 
solution to 100ml by adding distilled water. The final solution is taken for analysis. 
Qualitative analysis 
Sl. 
No. 
Experiment Observation Inference 
1 
Test for calcium: 
2ml of the above prepared extract is 
taken in a clean test tube and to this 
add 2ml of 4% Ammonium oxalate 
solution 
White 
precipitate is 
formed 
Indicates the 
presence of 
calcium 
2 
Test for sulphate: 
2ml of the extract is added to 5% 
Barium chloride solution 
A white 
precipitate is 
formed 
Indicates the 
presence of 
sulphate 
3 
Test for chloride: 
The extract is treated with silver 
nitrate solution 
 
White 
precipitate is 
formed 
Indicates the 
presence of 
chloride 
4 
Test for carbonate: 
The extract is treated with 
concentrated Hydrochloric Acid 
No brisk 
effervescence is 
formed 
Absence of 
carbonate 
5 
Test for starch: 
The extract is added with weak 
iodine solution 
Absence of 
blue color 
formation 
Absence of starch 
6 
Test for ferric iron: 
The extract is acidified with glacial 
acetic acid and potassium ferro 
cyanide 
No blue color is 
formed 
Absence of ferric 
iron 
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7 
Test for ferrous iron: 
The extract is treated with 
concentrated nitric acid and 
ammonium thiocyanate solution 
Blood red color 
is formed 
 
Indicates the 
presence of 
ferrous iron 
 
 
8 
Test for phosphate: 
The extract is treated with molybdate 
and concentrated nitric acid 
No yellow 
precipitate is 
formed 
Absence of 
phosphate 
9 
Test for albumin: 
The extract is treated with Esbach‟s 
reagent 
No yellow 
precipitate is 
formed 
Absence of 
albumin 
10 
Test for tannic acid: 
The extract is treated with ferric 
chloride 
No blue black 
precipitate is 
formed 
Absence of tannic 
acid 
11 
Test for unsaturation: 
Potassium permanganate is added to 
the extract 
Decolorization 
occurs 
Presence of 
unsaturated 
compound 
12 
Test for reducing sugar: 
5ml of benedict‟s qualitative solution 
is taken in attest tube and allowed to 
boil for 2 minutes and add 8 to 10 
drops of the extract and boil it again 
for 2 minutes 
No color 
change 
Absence of 
reducing sugar 
13 
Test for amino acid: 
One or two drops of the extract is 
placed on a filter paper allow it to 
dry. After drying 1% Ninhydrin is 
sprayed over the same and again dry 
Violet color is 
formed 
Presence of amino 
acid 
14 
Test for zinc: 
The extract is treated with potassium 
ferro cyanide 
No white 
precipitate is 
formed 
Absence of zinc 
 
Inference:  
The given sample of “kottai karanthai chooranam” contains calcium, sulphate, 
chloride, ferrous Iron, unsaturated compound and amino acid. 
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9.3 ANNEXURE – III 
FTIR SPECTROSCOPY ANALYSIS 
Fourier Transform Infra-Red analysis (FTIR) on Siddha monoherbal 
formulation of kottai karanthai chooranam 
Aim 
To standardize the Siddha monoherbal drug kottai karanthai chooranam 
through FTIR. 
Introduction 
FTIR is an important analytical technique to identify the functional groups 
which in turn represents the quality and consistency of the given sample. 
Materials & methods 
The ingredient kottai karanthai is purified and finely powdered as per Siddha 
literature Gunapadam Mooligai. The drug was analyzed using FTIR spectroscopy. 
 
Figure 9.3.1 FTIR Spectrum 
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Table 9.3.1 FTIR Spectrum values 
 
Results 
In Fourier Transform Infra-Red (FTIR) spectra analysis, kottai karanthai 
chooranam exhibit the peak value at 3865.35, 3832.56, 3348.42, 2974.23, 2943.37, 
2883.58, 2831.50, 2357.01, 1734.01, 1321.24, 1259.52, 1105.21, 534.28 having C-Br 
stretching, C-O stretching, S=O stretching, C=O stretching, O-H stretching, C-H 
Stretching, N-H stretching.  
This indicated the presence of organic functional groups such as halo 
compound, aliphatic ether, aromatic ester, sulfone, aldehyde, carboxylic acid, alkane, 
alcohol, secondary amine. 
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9.4 ANNEXURE – IV 
PHARMACOLOGICAL STUDY 
Anti-Inflammatory Activity of Kottai Karanthai Chooranam 
The anti-inflammatory activities of Kottai karanthai chooranam at 100 mg/kg 
doses & 200 mg/kg were evaluated using carrageenan-induced paw edema method. 
The inflammation was readily produced in the form of edema with the help of irritant 
such as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea 
weed (Rhodophyceae) and when injected cause the release of prostaglandins by the 
way it produces inflammation and edema. 
REQUIREMENTS 
Animal                                : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), Plethysmo meter. 
Test compounds                :   Kottai karanthai chooranam  
METHOD 
Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1)
 
The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v, 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the Kottai karanthai chooranam. The 
test Compounds dissolved with 2 ml sterile water given through orally 30 min before 
the carrageenan treatment. The paw volumes of the test compounds, standard and 
control groups were measured at 60,240,360 minutes of carrageenan treatment with 
the help of plethysmometer. Mean increase in paw volume was measured and the 
percentage of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
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Vc-mean increase in paw volume in control group of rats. 
TABLE 9.4.1 Anti-Inflammatory Activity of Kottai Karanthai Chooranam 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.70±0.96 - 
Group II 
   Std 
10mg/kg 
I.P.Diclofenac 
sodium 
2.20±0.40 61.40%*a 
Group III 
KOTTAI 
KARANTHAI 
CHOORANAM  
100mg/kg.Orally. 2.56±0.48 55.08%*a 
Group IV 
   KOTTAI 
KARANTHAI 
CHOORANAM  
200mg/kg.Orally.  2.40±0.52 57.89%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman‟s keul‟s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
 
Results 
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Anti- inflammatory activity 
Kottai karanthai chooranam, at doses 100mg/kg & 200mg/kg were tested for 
their Anti- inflammatory activity by using carrageenan Induced rat paw edema 
method and the results are tabulated in table no 1. The results reveals that both 
extracts of Kottai karanthai chooranam 100mg/kg & 200mg/kg doses possesses 
significant Anti- inflammatory activity when compared to control group at p<0.01. 
 
Figure 9.4.1 Anti-Inflammatory Activity of Kottai Karanthai Chooranam 
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Anti-histamine activity of Kottai karanthai chooranam 
Experimental Animals 
Wister rats (175-200 g) of either sex housed in standard conditions of 
temperature (22 ± 2°C), relative humidity (55 ± 5%) and light (12 hrs light/dark 
cycles) were used. They were fed with standard pellet diet and water ad libitum. The 
experimental protocol was approved by Institutional Animal Ethical Committee as per 
the guidance of CPCSEA, Histamine and acetylcholine induced bronchospasm in rats 
of either sex were divided into two groups of six animals each and exposed to 0.1% 
w/v of histamine dihydrochloride aerosol in histamine chamber. The progressive 
dyspnea was observed in animals when exposed to histamine aerosol. The end point, 
preconvulsion dyspnea (PCD) was determined from the time of aerosol exposure to 
the onset of dyspnoea leading to the appearance of convulsion. As soon as PCD 
commenced, the animals were removed from chamber and placed in fresh air. PCD of 
this time was taken as day 0 value. Both groups of rats were given KK drugs at the 
dose of 100 mg/kg, and 200 mg/kg, p.o. respectively, once a day for 7 days. On the 7 
day 2 h after the last dose, the time for the onset of PCD was recorded as on day 0. 
Same procedure was followed in another set of animals (n = 6) for acetylcholine 
induce bronchospasm study using 0.5% acetylcholine chloride. The percentage 
increased in time of PCD was calculated using following formula. Percentage 
increased in time of PCD = (1-T1/T2) × 100 
where T = time for PCD onset on day 0, T = time for PCD onset on day 7 
Table 9.4.2 Preconvulsive Dyspnea 
PRECONVULSIVE DYSPNEA (SEC) 
Treated 
Group 
HISTAMINE – induced 
Bronchospasm 
Acetylcholine - induced 
Bronchospasm 
 
KK 
Before 
treatment 
(control) 
After 
treatment 
% 
increase 
Before 
treatment 
(control) 
After 
treatment 
% 
increase 
100  
282.42 ± 
3.11* 
  
202.20 ± 
2.06* 
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mg/kg, p.o 105.60 ± 2.30 62.60 145.06 ± 1.12 28.25 
200 
mg/kg, p.o 
 
115.01 ± 1.88 
530.01 ± 
4.52* 
 
78.30 
 
136.02 ± 0.20 
252.02 ± 
3.06* 
 
46.06 
 
Mast Cell Degranulation Studies 
Histamine -Induced Mast Cell Degranulation in Rats 
Procedure 
Guinea RAT were divided in four groups, (n=5). The seven days drug 
treatment schedule was followed. 
Group-I received Distilled water (10 ml /kg p.o.)  
Group-II was treated with sodium cromoglycate (0.5mg/kg, intraperitonialy).  
Groups-III was treated with KK (100mg/kg), p.o 
Groups- IV were treated with KK (200 mg/kg, p.o) respectively 
On 7
th
 day, 2 hours after the assigned treatment mast cells were collected from 
the peritoneal cavity (Lakashmana et al, 2001, Lakadawala et al 1980).The RAT were 
anesthetized with ether and were injected 10 ml of normal saline solution into 
peritoneal cavity. The abdomen was gently massaged for 90 seconds. The peritoneal 
cavity was carefully opened and the fluid containing mast cells were aspirated and 
collected in siliconised test tube containing 7 to 10 ml of RPMI-1640 Medium (pH 
7.2- 7.4). The mast cells were then washed three times by centrifugation at low speed 
(400-500 rpm) and the pallet of mast cells was taken from the medium. Then 1% 
solution of arachodonic acid was added to the mast cell suspension (approximately 1 
x 10 6 /ml) and incubated at 37ºC in a water bath for 10 min. Later they were stained 
with 1 % Toludine blue (Dye) and observed under high power microscope field (400 
X). A total 100 cells were counted from different visual areas and percent protection 
against - induced mast cell degranulation was calculated 
 
140 
 
Table 9.4.3 Mast Cell Percentage 
MAST CELL PERCENTAGE 
Group Treatment Intact Disrupted % Protection 
1 
Distilled water (10 
ml/kg, p.o) 
23.7 ± 0.45 86.3 ± 0.45 - 
 
2 
Sodium cromoglycate 
(0.5mg/kg, i.p) 
 
73.20 ± 6.25** 
 
26.80 ± 6.25** 
 
86.03 
3 KK – (100mg/kg, p.o) 49.02 ± 0.23** 50.98 ± 0.23** 50.71 
4 
KK – (200 
mg/kg, p.o) 
40.05 ± 50.01** 59.95 ± 50.01** 59.68 
 
 
Figure 9.4.2 Mast Cell Percentage 
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Acute Anti-Inflammatory Study on Semparuthi Poo Ennai 
(Externally) 
By Hindpaw Method in Albino Rats 
Procedure 
Anti-inflammatory study of Semparuthi poo ennai was studied in healthy 
albino rats. Six rats were selected and divided in to three groups. To the first group 
distilled water was given and kept as control. The second group was given the 
standard drug diclofenacat a dose of 5 mg/kg body weight. The third group was treat 
with the test drug extermelly.Before the application of the drug the kind paw volume 
of all rats was measure .This was done by dipping the kind paw upto the tibio dorsal 
junction in a mercury plethysmography. Subcutaneous injection of 0.1 ml of 1%w/v 
carrageenin in water was made in to planter surface of both the kind paw of each rat. 
Three hours after injection the kind paw volume was measured once again. The 
difference between the initial and final volume would show the amount of 
inflammation.  
Taking the volume in the control group as 100% of inflammation the 
inflammatory or anti-inflammatory effect of the test group is calculated, injection of 
0.1 ml of 1%w/v of carrageenin in water was made into planter surface of both the 
hind paw if each rat. Three hours after carrageenin injection, the hind paw volume 
was measured once again. Difference between the initial and final value were noted 
and compared.  
The method is more suitable for studying anti-inflammatory activity on acute 
inflammation. 
The result of the drug is compared with the standard as well as control group in table 
9.4.4. 
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Table 9.4.4 Study of Acute –Inflammatory By Hind Paw Method 
Seri
al 
no 
Name of 
drugs/gro
ups 
Dose/1
00 
gram 
body 
weight 
Initia
l 
readi
ng 
avera
ge 
final 
readi
ng 
avera
ge 
Mean 
differe
nce 
Percenta
ge 
inflamma
tion 
Percent
age 
inhibiti
on 
remar
ks 
1 Water 2 ml 0.7 1.4  100   
2 
Diclofena
c 
5 
mg/kg 
0.9 1.2 0.3 25 75  
3 
Semparut
hi poo 
ennai 
 0.9 1.0 0.1 10 90  
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9.5 ANNEXURE - V 
ACUTE TOXICITY STUDY 
Effect of Acute Toxicity Study (14 Days) of KOTTAI KARANTHAI 
CHOORANAM 
Table 9.5.1 Physical and Behavioral Examinations. 
Group 
no. 
Dose(mg/kg) Observation sign No. of animal affected. 
Group-I 5mg/kg Normal 0 of 3 
Group- II 50mg/kg Normal 0 of 3 
Group-III 300mg/kg Normal 0 of 3 
Group-IV 1000mg/kg Normal 0 of 3 
Group-V 2000mg/kg Normal 0 of 3 
 
Table 9.5.2 Home cage activity 
Functio
nal and 
Behavio
ural 
observat
ion 
Observa
tion 
5mg/
kg 
Gro
up 
(G-
I) 
50mg
/kg 
(G-
II) 
300mg
/kg 
(G-
III) 
 
1000m
g/kg 
(G-IV) 
2000m
g/kg 
(G-V) 
Fem
ale 
n=3 
Fema
le 
n=3 
Femal
e n=3 
Female 
n=3 
Female 
n=3 
Body 
position 
Normal 3 3 3 3 3 
Respirati
on 
Normal 3 3 3 3 3 
Clonic 
involunt
ary 
Moveme
nt 
Normal 3 3 3 3 3 
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Table 9.5.3 Hand held observation 
Functi
onal 
and 
Behavi
oral 
observ
ation 
Observ
ation 
Con
trol 
5 
mg/ 
kg 
(G-
I) 
50 
mg/
kg 
(G-
II) 
300m
g/kg 
(G-
III) 
1000
mg/kg 
(G-
IV) 
2000
mg/kg 
(G-V) 
Fem
ale 
n=3 
Fe
mal
e 
n=3 
Fe
mal
e 
n=3 
Fema
le 
n=3 
Femal
e n=3 
Femal
e n=3 
Reacti
vity 
Normal 3 3 3 3 3 3 
Handli
ng 
Normal 3 3 3 3 3 3 
Tonic 
involunt
ary 
Moveme
nt 
Normal 3 3 3 3 3 
Palpebra
l closure 
Normal 3 3 3 3 3 
Approac
h 
response 
Normal 3 3 3 3 3 
Touch 
response 
Normal 3 3 3 3 3 
Pinna 
reflex 
Normal 3 3 3 3 3 
Tail 
pinch 
response 
Normal 3 3 3 3 3 
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Palpeb
ral 
closure 
Normal 3 3 3 3 3 3 
Lacrim
ation 
Normal 3 3 3 3 3 3 
Salivat
ion 
Normal 3 3 3 3 3 3 
Piloere
ction 
Normal 3 3 3 3 3 3 
Pupilla
ry 
reflex 
Normal 3 3 3 3 3 3 
Abdom
inal 
tone 
Normal 3 3 3 3 3 3 
Limb 
tone 
Normal 3 3 3 3 3 3 
 
Table 9.5.4 Mortality 
Group no Dose no(mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
 
Result 
  From acute toxicity study it was observed that the administration of 
KOTTAI KARANTHAI CHOORANAM at a dose of 2000 mg/kg to the rats do not 
produce drug-related toxicity and mortality. So No-Observed-Adverse-Effect- 
Level (NOAEL) of KOTTAI KARANTHAI CHOORANAM is 2000 mg/kg. 
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Discussion 
  KOTTAI KARANTHAI CHOORANAM was administered single time at 
the dose of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg and 2000mg/kg to rats and 
observed for consecutive 14 days after administration. Doses were selected based 
on the pilot study and literature review. All animals were observed daily once for 
any abnormal clinical signs. Weekly body weight and food consumption were 
recorded. No mortality was observed during the entire period of the study. Data 
obtained in this study indicated no significance physical and behavioural signs of 
any toxicity due to administration of KOTTAI KARANTHAI CHOORANAM at 
the doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
  At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups. Food consumption of all treated animals was found normal as 
compared to normal group. 
  Body weight at weekly interval was measured to find out the effect of 
KOTTAI KARANTHAI CHOORANAM on the growth rate. Body weight change 
in drug treated animals was found normal. 
 
Interpretation 
 KOTTAI KARANTHAI CHOORANAM was administered single time at 
the dose of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg and 2000mg/kg to rats and 
observed for consecutive 14 days after administration. Doses were selected based 
on the pilot study and literature review. All animals were observed daily once for 
any abnormal clinical signs. Weekly body weight and food consumption were 
recorded. No mortality was observed during the entire period of the study. Data 
obtained in this study indicated no significance physical and behavioural signs of 
any toxicity due to administration of KOTTAI KARANTHAI CHOORANAM at 
the doses of 5mg/kg, 50mg/kg , 300mg/kg, 1000mg/kg and 2000mg/kg to rats.  
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At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, 
Limb tone were observed. Functional and behavioral examination was normal in all 
treated groups. Food consumption of all treated animals was found normal as 
compared to normal group. 
Body weight at weekly interval was measured to find out the effect of 
KOTTAI KARANTHAI CHOORANAM on the growth rate. Body weight change 
in drug treated animals was found normal. 
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9.6 ANNEXURE – VI 
SUB-ACUTE TOXICITY STUDY 
Sub-Acute Toxicity Study in Wistar Rats to Evaluate Toxicity Profile of Kottai 
Karanthai Chooranam 
Table 9.6.1 Effect of Sub- Acute Dose (28 Days) of Kottai Karanthai 
Chooranam on Body Weight in Gram 
 
GROUP CONTROL LOW MID HIGH 
1
st
 day 122.3±1.03 125±1.543 124.3±2.231 126.3±2.23 
7
th
 day 132.3±1.03 131.3±1.343 131±2.113 137±2.11 
14
th
 day 134.1±1.004 102.3±1.12 102.4±2.012 103.4±2.012 
21
st
 day 103.3±2.120 110.2±1.501 104±1.131 105±1.13 
28
th
 day 113.3±1.041 112.3±1.202 143±2.0405 146±2.040 
 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett‟s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group. 
 
Table 9.6.2 Effect of Subacute Dose (28 Days) of Kottai Karanthai Chooranam 
    on Organ Weight (Physical Parameter) in Gram 
 
GROUP CONTROL LOW  MID HIGH 
HEART 0.43±0.02 0.64±0.04 .41±0.11 0.41±0.02 
LIVER 2.31± 0.23 2.33±0.23 2.20±0.01 2.23± 0.23 
LUNGS 1.31±0.10 0.31±0.14 0.50±0.24 1.43±0.10 
KIDNEY L 0.43±0.02 1.52±0.03 0.43±0.02 0.41±0.02 
 R 0.41±0.024 0.4-±0.02 0.41±0.024 0.42±0.024 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett‟s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table 9.6.3 Effect of Sub- Acute Dose (28 Days) of Kottai Karanthai 
Chooranam on Haematological Parameters 
   
Drug 
treatm
ent 
RBC 
millio
n 
cells/m
m
3
 
WBC  
cells/mm
3
 
Haemogl
obin gm 
% 
Differen
tial 
count 
% 
   
    
Neutop
hils 
Eosinop
hils 
Monoc
yte 
Limpoc
yte 
Control 
6.21±0
.40 
4252.41±2
3.32 
14.40±0.4
5 
31.27±1.
20 
1.53±0.1
1 
0.45±0.
15 
23.13±3
.32 
LOW 
4.47±0
.20 
4334.04±2
3.22 
12.20±0.4
3 
25.54±1.
41 
2.10±0.1
4 
0.52±0.
30 
23.22±3
.51 
MID 
5.33±0
.21 
4304.25±3
2.35 
14.11±1.0
3 
30.32±2.
22 
1.44±0.1
2 
0.62±0.
40 
23.13±3
.32 
HIGH 
6.26±0
.21 
4889.25±3
2.35 
13.11±1.0
3 
28.32±2.
22 
1.50±0.1
2 
0.74±0.
40 
24.13±3
.32 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by Dennett‟s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
        
Table 9.6.4 Effect of Sub- Acute Dose (28 Days) of Kottai Karanthai 
Chooranam on Biochemical Parameters 
Drug 
Treatment 
SGPT 
(IU/L) 
SGOT(IU/L) ALP(IU/L) 
Urea 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 42.14±3.02 42.24±4.31 243.12±11.32 35.35±3.00 0.64±0.03 
LOW 42.13±3.22 41.23±4.01 251.11±12.42 40.53±2.42 0.50±0.04 
MID 40.21±4.44 44.31±2.21 245.45±4.14 39.12±2.22 0.45±0.04 
HIGH 42.21±4.44 40.31±2.21 234.45±4.14 40.12±2.22 0.66±0.04 
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Table 9.6.5 Effect of Sub- Acute Dose (28 Days) of Kottai Karanthai 
Chooranam Biochemical Parameters 
 
GROU
P 
CONT
ROL 
KOTTAI 
KARANTHAI 
CHOORANAM(
200mg/kg) 
KOTTAI 
KARANTHAI 
CHOORANAM(
400mg/kg) 
KOTTAI 
KARAN
THAI 
CHOOR
ANAM 
(600mg/k
g) 
TOTA
L 
BILIR
UBIN 
(mg/dl) 
0.6±.0.
9 
0.88±0.7 0.88±0.6 0.74±0.19 
  
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett‟s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
 
Table 9.6.6 Effect of Sub-Acute Dose (28 Days) of Kottai Karanthai Chooranam 
on Food Intake in Gram 
 
GROUP CONTROL low mid high 
1
st 
DAY 18.33±13.5110 19.1672±14.3 12.10±21.71 17.5±7.62 
7
th 
DAY 15.5±11. 10.863±12.67 16.73±9.853 11.17±14.41 
14
th 
DAY 18.83±8.72 10.83±14.28 10±13.96 19.72±8.981 
21
st DAY
 11.87±12.4 15±8.466 15.88±9.43 19.17±8.02 
28
th
 DAY 12.10±11.38 18.38±11.50 10±8.90 10±7. 27 
 
Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett‟s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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Table 9.6.7 Effect of Sub-Acute Dose (28 Days) of Kottai Karanthai 
Chooranam on Water Intake in ml 
 
GR
OU
P 
CONT
ROL 
KOTTAI 
KARANTHAI 
CHOORANAM
(200mg/kg) 
KOTTAI 
KARANTHAI 
CHOORANAM
(400mg/kg) 
KOTTAI 
KARANTHAI 
CHOORANAM
(600mg/kg) 
1
st 
DA
Y 
98.8±1
3.50 
89.72±14.26 102.10±21.7199 67.5±7.3 
7
th 
DA
Y 
85.5±1
1.38 
100.863±12.770 76.3±9.36 81.67±14.40 
14
th 
DA
Y 
58.83±
8.77 
90.63±14.22 80±13.92 89.72±8.81 
21
st 
DAY
 
91.87±
12.49 
85±8.42 65.88±9.450 89.17±8.702 
28
th
 
DA
Y 
82.10±
11.340 
88.38±11.504 80±8.961 70±7.573 
 
Values are expressed as mean ± SEM Statisticalsignificance (p) calculated by one-
way ANOVA followed by Dennett‟s(n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groupswith control group 
 
Table 9.6.8 Effect of Sub Acute Doses (28 Day) of Kottai Karanthai 
Chooranam on Electrolytes 
GROUP 
CONTR
OL 
KOTTAI 
KARANTHA
I 
CHOORANA
M 
KOTTAI 
KARANTHA
I 
CHOORANA
M 
KOTTAI 
KARANTHA
I 
CHOORANA
M 
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Values are expressed as mean ± SEM Statistical significance (p) calculated by one-
way ANOVA followed by Dennett‟s (n=6); NS- non-significant, *p<0.05, 
**p<0.01, ***p<0.001, 
 
Results 
Clinical Signs 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality 
All animals in control and in all the treated dose groups survived 
throughout the dosing period of 28 days. 
 Body weight 
Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period 
of 28 days. 
Food consumption 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight 
Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.22 Comparison of organ weights of treated animals with respective 
control animals on day 29 was found to be comparable similarly. 
 
(200mg/kg) (400mg/kg) (600mg/kg) 
Sodium 
(mg/dl) 
163.90±0.
5 
164.0±0.2 161±0.1 171.70±0.60 
Calcium(mg/
dl) 
12.0±0.89 13.0±0.3* 14.7±0.19* 16.0±0.1* 
Phosphorus 
(U/L) 
8.8±0.17 8.10±0.15
ns 
8.0±0.091
ns 
8.7±0.2* 
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Hematological investigations 
The results of hematological investigations conducted on day 29 revealed 
following significant changes in the values of different parameters investigated 
when compared with those of respective controls; however, the increase or 
decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations 
Results of Biochemical investigations conducted on the day 29th and 
recorded in Table no 24, 25 revealed the following significant changes in the values 
of hepatic serum enzymes studied. When compared with those of respective 
control. However, the increase or decrease in the values obtained was within 
normal biological and laboratory limits. 
 
Interpretation 
1)  All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29th, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29
th
, no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
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9.7 ANNEXURE - VII 
ANTI-MICROBIAL STUDY 
Aim 
To study the anti-microbial action of “kottai karanthai chooranam” against 
Staphylo coccus aurenus, pseudomonas aeruginosae. 
Medium 
Muller Hinton agar 
Components of medium 
Beef extract  - 300gms/lit 
Agar   - 17gms/lit 
Starch   - 1.5gms/lit 
Casein Hydrpxylate - 17.5gms/lit 
Distilled water - 1000ml 
PH   - 7.6 
Procedure 
The media was prepared from the above components and poured and dried on 
a petridish. The organism was streaked on the medium and the test drug (1gm drug in 
250ml of water) was placed on the medium. This is incubated at 37°C for one 
overnight and observed for the susceptibility shown up clearance around the drug. 
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Figure 9.7.1 Anti-Microbial Test Report 
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Figure 9.7.2 Anti-microbial Culture dish 
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9.8 ANNEXURE - VIII 
DERMAL TOXICITY STUDY 
Evaluation of Acute Toxicity Study of Dm 3 
Test Method  
Preparation of the test item  
The test item was applied as such onto the skin of rats. Test item was prepared under 
dark conditions. Test Procedure A range finding study using a male and a female rat 
at dose 2000 mg/Kg b.w. was carried out in order to establish the dose levels for the 
main study. Approximately, 24 hours before the treatment, around 10% dorsal skin 
area of each rat was clipped free of hair, without any abrasion. The appropriate 
amount of the test item was applied uniformly over the clipped area of each rat. After 
the application, the test item was held in contact with the skin for a period of 24 
hours, using a porous gauze dressing (Modern Health Care, B. No.: 141, Expiry: 
October 2017) and bandaged with non-irritating adhesive tape. After 24 hours, the 
residual test item was wiped gently from the skin using wet cotton, soaked in water. 
Neck collar was used to prevent the ingestion of the test item from the application 
site. No mortality was observed for 4 days in the range finding study at 2000 mg/Kg 
b.w. Based on the results from the range finding experiment, limit test was chosen. In 
the limit test, 3 male and 3 female rats were exposed to 2000 mg/Kg b.w. 
Effect of Acute Toxicity Study (14 Days) of DM 3 
Table 9.8.1 Mortality 
Group no Dose (mg/kg) Mortality 
Group-I 5(mg/kg) 0 of 3 
Group-II 50(mg/kg) 0 of 3 
Group-III 300(mg/kg) 0 of 3 
Group-IV 1000(mg/kg) 0 of 3 
Group-V 2000(mg/kg) 0 of 3 
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Table 9.8.2 Effect of Sub- Acute Dose (28 Days) of Dm 3 on Body Weight in 
Gram 
GROUP CONTROL LOW MID HIGH 
1
st
 day 120.3±1.03 123±1.543 120.3±2.231 120.3±2.23 
7
th
 day 131.3±1.03 130.3±1.343 130±2.113 136±2.11 
14
th
 day 133.1±1.004 131.3±1.12 131.4±2.02 132.4±2.02 
21
st
 day 122.3±2.120 129.2±1.501 123±1.131 124±1.13 
28
th
 day 124.3±1.041 116.3±1.202 118±2.05 116±2.040 
 
Table 9.8.3 Effect of Skin Reaction 
SKIN 
REACTI
ON 
Observati
on 
Contr
ol 
5 mg/ 
kg 
(G-I) 
50 
mg/k
g 
(G-II) 
300mg/
kg 
(G-III) 
1000mg/
kg 
(G-IV) 
2000mg/
kg 
(G-V) 
Femal
e n=3 
Fema
le n=3 
Fema
le n=3 
Female 
n=3 
Female 
n=3 
Female 
n=3 
ERYTHE
A 
Normal - - - - - - 
EDEMA Normal - - - - - - 
SCALING      
OF 
EPIDERM
IS 
Normal - - - - - - 
 
Discussion 
  DM 3 was administered single time at the dose of 5mg/kg, 50mg/kg , 
300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for consecutive 14 days 
after administration. Doses were selected based on the pilot study and literature 
review. All animals were observed daily once for any abnormal clinical signs. Weekly 
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body weight and food consumption were recorded. No mortality was observed during 
the entire period of the study.  
  Body weight at weekly interval was measured to find out the effect of DM 3 
on the growth rate. Body weight change in drug treated animals was found normal. 
Interpretation 
 DM 3 was administered single time at the dose of 5mg/kg, 50mg/kg, 
300mg/kg, 1000mg/kg and 2000mg/kg to rats and observed for consecutive 14 days 
after administration. Doses were selected based on the pilot study and literature 
review. All animals were observed daily once for any abnormal clinical signs. Weekly 
body weight recorded. No mortality was observed during the entire period of the 
study. Data obtained in this study indicated no significance toxicity due to 
administration of DM 3 at the doses of 5mg/kg, 50mg/kg, 300mg/kg, 1000mg/kg and 
2000mg/kg to rats.  
Body weight at weekly interval was measured to find out the effect of DM 3on 
the growth rate. Body weight change in drug treated animals was found normal. 
Results 
Clinical Signs 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
Body weight 
Results of body weight determination of animals from control and different 
dose groups exhibited comparable body weight gain throughout the dosing period of 
28 days. 
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Interpretation 
1)  All the animals from control and all the treated dose groups up to 15ml/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days. 
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9.9 ANNEXURE - IX 
ASSESSMENT FORMS 
FORM I : Screening of Selection Proforma 
FORM II : Consent Form (Tamil and English) 
FORM III : History Proforma on Enrollement 
FORM IV : Clinical Assessment Form 
FORM V : Laboratory Investigations Form 
FORM VI : Drug Compliance Form 
FORM VII : Adverse Drug Reaction Form 
FORM VIII : Withdrawal Form 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM-I 
(SCREENING AND SELECTION PROFORMA) 
1. OPD/IPD No.:    2. Date:     
3. SI. No.:    4. Name:      5. Age:   
6. Gender:   7. Phone No.:    
INCLUSION CRITERIA: 
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Age: 15 -60 years 
Sex: Both male and female 
 Silvery scaly patches 
 Coin shaped lesions______ 
 Scaling with (or) without Itching 
 Patients who are willing to give specimen of blood for the investigation 
wherever required. 
 Patient willing to sign the informed consent stating that he/she will 
consciously stick to the treatment but can OPD out of the trial of his/ her own 
conscious discretion. 
EXCLUSION CRITERIA: 
 Evidence of any skin condition other than psoriasis 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and development of adverse reactions during drug trial. 
 Poor patient compliance and defaulters 
 Patient turned unwilling to continue in the course of clinical trial 
 Occurrence of any serious illness 
 
DATE:  
STATION: 
 
Signature of the Investigator 
 
 
Signature of the Guide/HOD 
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அ஧சிண஧் சி஡்஡ ஥மே஡்து஬க் கன்லூ஧ி ஥ந்று஥் ஥மே஡்து஬஥றண 
தாறப஦ங்சகாடற்ட 
தட்டச஥ந்தடித்பு சிநத்பு ஥மே஡்து஬஡்துறந 
 
தகாடற்டக் க஧஢்ற஡ சூ஧஠஥் ஥ந்று஥் தே஥்தமே஡்தி பூ 
஋஠்த஠஦், ச஦ாகா ஆகி஦஬ந்றிண் த஧ிக஧ித்பு திநறணக் 
க஠்டறிம௅஥் ஥மே஡்து஬ ஆ஦்வு ஒத்பு஡ன் தடி஬஥் ஆ஦்஬ாப஧ான் 
ோண்நபிக்கத்தடட்்து. 
 
஠ா஡் இ஠்ட ஆத்வபக் குறிட்ட அவ஡ட்து வி஢஥ங்வநப௉ண் 
ந஠ாதாநிக்கு பு஥ிப௉ண் பவகபே஧் எடுடத்ுவ஥ட்நட஡் எ஡ 
உறுதிதநிக்கிந஦஡் 
நடதி:     
இ஝்ண்:     
 
ஆத்பாந஥ ்வகமதா஢்஢ண்  துவ஦ட்டவ஧ப஥ ்வகமதா஢்஢ண்
      
ம஢த஥ ்         ம஢த஥ ்
ச஢ா஦ாபிம௃ண் ஒத்பு஡ன் 
எ஡்஡ி஝ண் இ஠்ட ணருட்துப ஆத்வி஡் கா஥ஞட்வடப௉ண் 
ணரு஠்தி஡் ட஡்வண ண஦்றுண் ணருட்துப பழிப௅வ஦வத஢் ஢஦்றிப௉ண் 
மடா஝஥஠்்து எ஡து உ஝஧் இதக்கட்வட கஞ்காஞிக்கவுண், 
அடவ஡஢் ஢ாதுகாக்கவுண் ஢த஡்஢டுண் ணருட்துப ஆத்வுக்கூ஝ 
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஢஥ிநசாடவ஡கந் ஢஦்றிப௉ண் திரு஢்தி அநிக்குண் பவகபே஧் ஆத்வு 
ணருட்துப஥ா஧் விநக்கிக் கூ஦஢்஢஝்஝து. 
஠ா஡் இ஠்ட ணருட்துப ஆத்வி஡் ந஢ாது கா஥ஞண் எதுவுண் கூ஦ாண஧் 
எ஢்ம஢ாழுது நபஞ்டுணா஡ாலுண் இ஠்ட ஆத்விலிரு஠்து எ஡்வ஡ 
விடுவிட்துக் மகாந்ளுண் உ஥ிவணவத மட஥ி஠்திருக்கி஡்ந஦஡். 
஠ா஡் எ஡்னுவ஝த சுட஠்தி஥ணாகட ் நட஥வ்ு மசத்ப௉ண் உ஥ிவணவதக் 
மகாஞ்டு காநாஜ்சக஢்஢வ஝ எ஡்னுண் ந஠ாத்க்கா஡ மகா஝வ்஝க் 
க஥஠்வட சூ஥ஞண் ண஦்றுண் மசண்஢ருட்தி பூ எஞ்மஞத், நதாகா 
ஆகிதப஦்றி஡் ஢஥ிக஥ி஢்பு தி஦வ஡க் கஞ்஝றிப௉ண் ணருட்துப 
ஆத்வி஦்க்கு எ஡்வ஡ உ஝்஢டுட்திக் மகாந்ந ஑஢்புட஧் 
அநிக்கிந஦஡்.  
 
 
நடதி:      வகமதா஢்஢ண்  
       
இ஝்ண்:       ம஢த஥ ்
 
     சா஝்சிக்கா஥஥ ் வகமதா஢்஢ண் 
        
ம஢த஥ ்
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM-II 
CONSENT FORM 
Certificate by Investigator 
I certify that I have disclosed all details about the study in the terms readily 
understood by the Patient. 
Date: …………….. 
 
Signature of the Investigator     Signature of the Guide/HOD 
 
Name: ……………………………..  Name: …………………………… 
 
Consent by Patient 
I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow-up including 
the laboratory investigations to be performed to monitor and safeguard my body 
functions. 
I am aware of my right to withdraw from the trial at any time during the 
course of the trial without having to give the reasons for doing so. 
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I, exercising my free power of choice, hereby give my consent to be included 
as a clinical trial of KOTTAIKARANTHAI CHOORANAM [INTERNAL], 
SEMPARUTHI POO ENNAI [EXTERNAL] AND YOGA THERAPY FOR THE 
TREATMENT OF KALANJAGAPADAI [PSORIASIS]. 
Date:……………….. Name: …………… Signature: ………………………………… 
 
Date:………………..Name:………………Signature of Witness: ……………………. 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM III 
HISTORY PROFORMA ON ENROLLMENT 
 
1. Serial No of the case: _______________       2. OPD/IPD No:_________ 
                
3.Name: ____________           4. Gender:   
                
                
5. Age (years): _________ DOB              
    Date Month Year 
6. Address: 
-------------------------------------
-              
  --------------------------------------           
  --------------------------------------           
7. A. Occupation:  -----------------------------        B. Income ----------------- 
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8. Educational Status:  A) Illiterate   B)Literate       
9. Height: ---------- cms 
    
kg 
      
10.Weight:----------        
 
11. Complaints and 
Duration: 
12. Past History  
Hypertension ______________ 
Diabetes mellitus ______________ 
Asthma ______________ 
PT ______________ 
Other ______________ 
 
13. HABITS                            
                          
A) Smoking: 1. Yes   duration ________ years;   Number - _____  2. No     
                          
                       
B) Alcoholism: 1. Yes  duration ________ years;   Quantity- ____ ml 2. No     
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C) Tobacco chewing: 1. Yes    duration ________ years     2.No     
                        
D) Betel chewing : 1. Yes    duration ________ years     2.No     
                         
                       
14. Dietary style: A. Pure vegetarian     B.Non-vegetarian     C. Mixed diet  
                      
15. Drug history: Had the patient been treated before with allopathy drug? 
  
A) Yes 
      
2) No 
                
                        
                       
                       
16 Marital status : 1.Married      2.Unmarried             
17. Family history : 
                        
                        
 
Whether this problem runs in family? 
 
1. Yes 
        
2.No 
  
             
 
(If yes, mention the relationship) 
                   
                    
18. Bowel habits & micturition:Normal 
   
Abnormal 
    
       
 (Details of an abnormality)                         
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19. Psychological state:Normal    Anxiety      Depression   
                 
 
 
 
Signature of the Investigator              Signature of the Guide/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM IV 
CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. S.No: _______ 2. OPD/IPD No : __________ 
 
3. Name: _______________________ 4. Gender: __________ 
 
5. Date of assessment: _____________ 
 
SIDDHA SYSTEM OF EXAMINATION 
 
1.NILAM: [ LAND WHERE PATIENT LIVED MOST]     
           
Kurinji  Mullai  Marutham   Neithal  Palai  
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(Hilly terrain) (Forest range) (Plains) (Coastal belt) (Arid regions) 
 
2. KAALAM:     
Kaarkalam - 
 
      Pinpanikalam  -______  
Koothirkalam - 
 
      Ilavenil  - ________ - 
 
 
 
Munpanikalam   _________  
  
Muthuvenil  _______   
3. THEGI: 
 
 
4. GUNAM: 
 
Sathuvam-___  Rasatham -______  Thamasam -_______ 
     
 
5.IMPORIGAL (SENSORY ORGANS) : 
 
Mei (Skin): 
Vai (Buccal Cavity): 
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Kan(Eyes) : 
Mooku(Nose): 
Sevi(Ears) : 
 
6.KANMENDRIYAM (MOTOR ORGANS) : 
 
Kai (Upper limb): 
Kaal(Lower limb): 
Vai(Buccal Cavity): 
Eruvai(Excretory organs): 
Karuvai(Reproductive organs): 
 
7.UYIR THATHUKKAL: 
 
A)VATHAM: 
 
Pranan: 
Abanan: 
Viyanan: 
Udhanan: 
Samanan: 
Nagan: 
Koorman: 
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Kirukaran: 
Devathathan: 
Dhananjeyan: 
 
B)PITHAM: 
 
Analpitham: 
Ranjagam: 
Sathagam: 
Prasagam: 
Aalosagam: 
 
C)KABAM: 
 
Avalambagam: 
Kilaethagam: 
Pothagam: 
Tharpagam: 
Santhigam: 
 
8.UDAL THATHUKKAL: 
 
Saaram[Chyme]: 
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Senneer[Blood]: 
Oon[Muscle]: 
Kozhuppu[Fat]: 
Enbu[Bone]: 
Moolai[Bone Marrow]: 
Sukkilam/Suronitham 
[Genital Discharges] : 
9.ENVAGAI THERVUGAL: 
 
Naadi: 
Sparisam: 
Naa: 
Niram: 
Mozhi: 
Vizhi: 
Malam: 
Moothiram: 
 
10.NEER KURI: 
 
Niram: 
Manam: 
Nurai: 
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Edai: 
Enjal: 
 
11.NEI KURI: 
 
GENERAL EXAMINATION: 
 
Conscious level: 
Body weight: 
Height: 
BMI: 
Built: 
Nourishment: 
Temperature: 
Blood Pressure: 
Pulse rate: 
Heart rate: 
Respiratory rate: 
Anaemia: 
Jaundice: 
Clubbing: 
Cyanosis: 
Pedal oedema: 
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Significant Lymphadenopathy: 
 
SYSTEMIC EXAMINATIONS: 
 
Central Nervous System: 
Cardio Vascular System: 
Respiratory System: 
Gastro Intestinal System: 
Genito Urinary System: 
 
CLINICAL EXAMINATION OF SKIN: 
 
RIGHT LEFT 
Site 
COLOUR 
 
SHAPE 
Irregular Coin shaped dispensed 
SCALING 
Mild moderate severe 
ITCHING 
 No Mild moderate severe 
ERYTHEMA 
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 Absent  present 
BLEEDING 
 Absent  present 
CRUSTING 
 Absent  present 
LICHENIFICATION 
 Absent  present 
OOZING 
 No Mild moderate severe 
AUSPITZ SIGN 
 Absent  present 
KOEBNER‟S PHENOMENON 
 Absent  present 
CANDLE GREASE REGION 
Absent  present 
ULCERATION 
 
MACULE/PAPULE/PUSTULE/BLISTER/VESICLE  
PIGMENTATION 
 Absent  /hype /hyper 
 
EXAMINATION OF NAIL 
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PITTING 
Absent  present 
THICKENING 
 Absent  present 
COLLECTION OF HYPERKERATOTIC DEBRIS 
Absent  present 
EXAMINATION OF JOINTS 
 
Joint involvement: yes no 
 
If yes ………………………….. 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM V 
LABORATORY INVESTIGATION FORM 
SI. No: 
OPD/IPD No: 
Name: 
Age/Sex: 
I.BLOOD 
  Before Treatment After Treatment 
1 TC (cells/mm)   
    
2 DC (%)   
    
 a)Neutrophils   
    
 b)Lymphocytes   
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 c)Monocytes   
    
 d)Eosinophils   
    
3 ESR(mm)   
    
 a)1/2 hour   
    
 b)1 hour   
    
4 Haemoglobin   
    
5 Blood glucose   
    
6 Blood urea/ creatinine   
    
7 Serum cholesterol   
 
II. URINE 
  Before Treatment After Treatment 
    
1 Albumin   
    
2 Sugar   
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3 Epithelial cells   
    
4 Pus cells   
    
5 Red blood cells   
    
6 Casts/Crystals   
    
 
 
Date 
 
Station 
 
Signature of the Investigator    Signature of the Guide/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM VI 
DRUG COMPLIANCE FORM 
OPD/ IPD No: ____________ DOA : ___________ 
Name: _____________________ 
Age/Sex: ___________ Sl. No: _________ 
Name of the Drug : KOTTAIKARANTHAI CHOORANAM 
     
     
     
     
     
     
     
     
 
DATE: 
 
SIGNATURE OF THE INVESTIGATOR    SIGNATURE OF THE GUIDE/HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL STUDY TO EVALUATE THE THERAPEUTIC 
EFFICACY OF SIDDHA MONOHERBAL MEDICINE KOTTAIKARANTHAI 
CHOORANAM [INTERNAL], SEMPARUTHI POO ENNAI [EXTERNAL] AND 
YOGA THERAPY FOR THE TREATMENT OF KALANJAGAPADAI 
[PSORIASIS] 
FORM VII 
ADVERSE DRUG REACTION FORM 
Name: ________________________ OPD/ IPD No: __________ 
Age: ________ Gender: ________ 
Date of trial commencement: ___________ 
Date of withdrawal from trial: ___________ 
Description of adverse reaction: __________________________________ 
_____________________________________________________________________
___ 
Date: 
 
Station: 
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[PSORIASIS] 
FORM VIII 
WITHDRAWAL FORM 
Name: ________________________ OPD/ IPD Number: __________  
Age : ________ Gender : ________    
Date of trial commencement: ___________       
Date of withdrawal from trial: ___________       
Reasons for withdrawal:     YES NO 
Long absence in without reporting 
Irregular treatment 
Shift of locality 
Increase in severity of symptoms 
Development of severe adverse drug 
reactions 
Date: 
Station:        
        
SIGNATURE OF THE INVESTIGATOR       SIGNATURE OF THE GUIDE/HOD 
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